YEDİTEPE UNIVERSITY

FACULTY OF MEDICINE

PHASE III

ACADEMIC PROGRAM BOOK

2017 - 2018

Student's
Name : .....
Number : .....

YEDİTEPE UNIVERSITY

FACULTY OF MEDICINE

PHASE III

Contents

YEDİTEPE UNIVERSITY FACULTY OF MEDICINE

AIM OF MEDICAL EDUCATION PROGRAM

*"Consensus Commission Report" based on draft compiled at "*Workshop for Revision of Aim and Outcomes of Medical Education Program at Yeditepe University Faculty of Medicine*"
**© 2011, Yeditepe University Faculty of Medicine

AIM

The aim of medical education program ***is to graduate physicians*** who

- **are aware of** the local and global health issues
- **have acquired competence** in knowledge, skills and attitudes to manage and provide primary health care service
- **know**, **apply** and **care** for ethical principles of the medical profession
- **keep up with** current knowledge at national and international level
- **are capable of** systematical thinking
- **are** investigative and questioning
- continually **renovate** and **improve** themselves
- **are capable of** teamwork
- **use** technology competently in medicine and related areas
- **have** effective communication skills
- **have** community leadership qualifications

YEDİTEPE UNIVERSITY FACULTY OF MEDICINE

PROGRAM OUTCOMES OF MEDICAL EDUCATION PROGRAM

*©2015 Yeditepe Üniversitesi Tıp Fakültesi (Yeditepe University Faculty of Medicine)
All Rights Reserved.
**No part of this publication may be reproduced, stored in a retrievalsystem or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission of Yeditepe University Faculty of Medicine.*

Abbreviations: PO: Program Outcomes, POD: Program Outcomes Domain, PODG: Program Outcomes Domain Group

PODG.1. Basic Professional Competencies

POD.1.1. Clinical Competencies

PO.1.1.1. ***values*** preventive health services, ***offers*** primary prevention (i.e. prevention of diseases for the protection of health), secondary prevention (i.e. early diagnosis and treatment) tertiary prevention (i.e. rehabilitation) and quaternary prevention (i.e. prevention of excessive and unnecessary diagnosis and treatment) services, ***provides*** consultancy on these issues.
PO.1.1.2. ***employs*** a patient-centered approach in patient management.
PO.1.1.3. ***recognizes*** most frequently occurring or significant clinical complaints, symptoms, signs, findings and their emergence mechanisms in clinical conditions.
PO.1.1.4. ***takes*** medical history from the applicant himself/herself or from the individual's companions.
PO.1.1.5. ***does*** general and focused physical and mental examination.
PO.1.1.6. ***interprets*** findings in medical history, physical and mental examination.
PO.1.1.7. ***employs*** diagnostic procedures that are used frequently at the primary health care level.
PO.1.1.8. ***selects*** tests that have evidence-based high efficacy at the primary health care level and ***interprets*** results.
PO.1.1.9. ***makes*** clinical decisions using evidence-based systematic data in health care service.
PO.1.1.10. ***performs*** medical interventional procedures that are used frequently at the primary health care level.
PO.1.1.11. ***manages*** healthy individuals and patients in the context of health care services.
PO.1.1.12. ***keeps*** medical records in health care provision and ***uses*** information systems to that aim.

POD.1.2. Competencies related to Communication

PO.1.2.1. throughout his/her career, ***communicates*** effectively with health care beneficiaries, co-workers, accompanying persons, visitors, patient's relatives, care givers, colleagues, other individuals, organizations and institutions.
PO.1.2.2. ***collaborates*** as a team member with related organizations and institutions, with other professionals and health care workers, on issues related to health.
PO.1.2.3. ***recognizes*** the protection and privacy policy for health care beneficiaries, co-workers, accompanying persons and visitors.
PO.1.2.4. ***communicates*** with all stakeholders taking into consideration the socio-cultural diversity.

POD.1.3. Competencies Related to Leadership and Management

PO.1.3.1. ***manages*** and ***leads*** within the health care team in primary health care organization.
PO.1.3.2. ***recognizes*** the principles of health management and health sector economy, models of organization and financing of health care services.
PO.1.3.3. ***recognizes*** the resources in the health care service, the principles for cost-effective use.

POD.1.4. Competencies related to Health Advocacy

PO.1.4.1. ***recognizes*** the health status of the individual and the community and the factors affecting the health, ***implements*** the necessary measures to prevent effects of these factors on the health.
PO.1.4.2. ***recognizes*** and ***manages*** the health determinants including conditions that prevent access to health care.

POD.1.5. Competencies related to Research

PO.1.5.1. ***develops***, ***prepares*** and ***presents*** research projects

POD.1.6. Competencies related to Health Education and Counseling

PO.1.6.1. ***provides*** consultancy services and ***organizes*** health education for the community to sustain and promote the health of individual and community**.**

PODG.2. Professional Values and Perspectives

POD.2.1. Competencies related to Law and Legal Regulations

PO.2.1.1. ***performs*** medical practices in accordance with the legal framework which regulates the primary health care service.

POD.2.2. Competencies Related to Ethical Aspects of Medicine

PO.2.2.1. ***recognizes*** basic ethical principles completely, and ***distinguishes*** ethical and legal problems.

PO.2.2.2. ***pays importance to*** the rights of patient, patient's relatives and physicians, and ***provides*** services in this context.

POD.2.3. Competencies Related to Social and Behavioral Sciences

PO.2.3.1. ***relates*** historical, anthropological and philosophical evolution of medicine, with the current medical practice.

PO.2.3.2. ***recognizes*** the individual's behavior and attitudes and factors that determine the social dynamics of the community.

POD.2.4. Competencies Related to Social Awareness and Participation

PO.2.4.1. ***leads*** community with sense of responsibility, behavior and attitudes in consideration of individual behaviors and social dynamics of the community, and if there is a necessity, ***develops*** projects directed towards health care services.

POD.2.5. Competencies Related to Professional Attitudes and Behaviors

PO.2.5.1. ***displays*** a patient-centered and holistic (biopsychosocial) approach to patients and their problems.

PO.2.5.2. ***respects*** patients, colleagues and all stakeholders in health care delivery.

PO.2.5.3. ***displays*** the proper behavior in case of disadvantaged groups and situations in the community.

PO.2.5.4. ***takes*** responsibility for the development of patient safety and healthcare quality.

PO.2.5.6. ***evaluates*** own performance as open to criticism, ***realizes*** the qualifications and limitations.

PODG.3. Personal Development and Values

POD.3.1.Competencies Related to Lifelong Learning

PO.3.1.1. ***embraces*** the importance of lifelong self-learning and ***implements***.

PO.3.1.2. ***embraces*** the importance of updating knowledge and skills; ***searches*** current advancements and ***improves*** own knowledge and skills.

PO.3.1.3. ***uses*** English language at least at a level adequate to follow the international literature and to establish communication related to the profession.

POD.3.2. Competencies Related to Career Management

PO.3.2.1. ***recognizes*** and ***investigates*** postgraduate work domains and job opportunities.

PO.3.2.2. ***recognizes*** the application requirements to postgraduate work/job domains, and ***distinguishes*** and ***plans*** any requirement for further training and work experience.

PO.3.2.3. ***prepares*** a resume, and ***recognizes*** job interview methods.

POD.3.3. Competencies Related to Protection and Development of Own Physical and Mental Health

PO.3.3.1. ***implements*** the rules of healthy living.

PO.3.3.2. ***displays*** appropriate behavior specific to work under stressful conditions.

PO.3.3.3. ***uses*** self-motivation factors.

COORDINATION COMMITTEES

(TEACHING YEAR 2017–2018)

PHASE-III COORDINATION COMMITTEE

Bayram YILMAZ, PhD, Prof. (Coordinator)
Hasan AYDIN, MD, Assoc. Prof. (Co-coordinator)
Ayşegül Ç. KUŞKUCU, MD, Asst. Prof. (Co-coordinator)
Hale ARIK TAŞYIKAN, MD, Asst. Prof. (Co-coordinator)
Serdar ÖZDEMİR, MD, Asst. Prof. (Co-coordinator)
Barış Ata BORSA, Asst. Prof. (Co-coordinator)

ICP-III COORDINATION COMMITTEE

Özlem TANRIÖVER, MD, Assoc. Prof. (Coordinator)
Ayşe Arzu AKALIN, MD, Asst. Prof. (Co-coordinator)

DESCRIPTION and CONTENT

Physiopathological process and pathological process.

Infectious Diseases, Cardiovascular System, Respiratory System, Hematopoietic System, Gastrointestinal System, Endocrine System, Urogenital System, Nervous System, Psychiatry, Musculoskeletal System, Basic Clinical Skills, Biomedical Ethics and Deontology, Biostatistics.

Emergency Medicine, Family Medicine, Anesthesiology and Reanimation, Neurosurgery, Biostatistics, Biomedical Ethics and Deontology, Pediatrics, Pediatric Surgery, Pediatric Psychiatry, Endocrinology, Infectious Diseases, Immunology, Phytotherapy, Physical Therapy and Rehabilitation, Physiopathology, Gastroenterohepathology, General Surgery, Pulmonary Diseases, Thoracic Surgery, Ophtalmology, Public Health, Hematology/Oncology, Obstetrics and Gynecology, Cardiology, Otorhinolaryngology, Nephrology, Neurology, Orthopedics and Traumatology, Pathology, Psychiatry, Radiology, Rheumatology, Medical Pharmacology, Medical Genetics, Medical Microbiology, Urology, Medical Education.

AIMS and LEARNING OBJECTIVES of PHASE III

AIMS

In evidence based manner:
1. ***to remind*** anatomy, histology and physiology of body systems,
2. ***to convey*** necessary knowledge, related to body systems, on prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions.
3. at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
3.1. ***to convey*** necessary knowledge on risk factors, etiopathogenesis, physiopathology, and pathology,
3.2. ***to convey*** knowledge on epidemiology,
3.3. ***to convey*** knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
3.4. ***to convey*** necessary knowledge on health care processes, clinical decision making process, clinical decisions and clinical practices, with performance measures, for managing at the level of 7primary health care service,
4. ***to convey*** knowledge on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
5. ***to convey*** knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
6. ***to convey*** knowledge on biostatistical analysis,
7. ***to convey*** basic legal and ethical principles that should be followed in practice of medical profession,
8. ***to equip with*** basic and advanced professional and clinical (interventional or non-interventional) skills necessary for practice of medical profession.

LEARNING OBJECTIVES

At the end of this phase, student should be able to:
1.0. ***recall*** anatomy, histology and physiology of body systems.
2.0. ***list*** necessities for prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions in relation to body systems.
3.0. ***explain*** risk factors and etiopathogenesis, at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
4.0. at cellular or tissue level,
4.1. ***recognize*** morphological characteristics,
4.2. ***show*** basic pathological changes that occur in clinical conditions.
5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
5.1. ***explain*** mechanisms of destruction at molecule, cell, tisssue, organ, system, multi-system and organismal level,
5.2. ***describe*** structural and functional changes caused,
5.3. ***list*** clinical courses in time.
6.0. ***explain*** mechanisms of emergence for frequently encountered;
6.1. clinical complaints,
6.2. symptoms,
6.3. signs,
6.4. laboratory and imaging findings
of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
7.0. at multi-system level or related to a body system,
• for healthy conditions in an individual or community with a request, or
• in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
• for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
explain in an evidence-based manner and with performance measures from the aspects of reliability, practicality and outcomes,
• health care processes,
• acquisition of subjective or objective data, information and knowledge required for clinical decision making,
• clinical decision making process,

• clinical decisions and
• clinical practices
which are required for management at primary health care service level.
7.1. practice of history taking and physical examination (*cardiovascular-C2, pulmonary-C2, gastrointestinal-C4, gynecological-C5, breast-C5, neonatal, prepubertal/pubertal-C6, neurological/neuropsychiatric-C7, musculoskeletal-C8*)
7.2. evaluation of emergency case (*sepsis and septic shock-C1, dyspnea-C2, acute abdominal pain-C4, urological emergencies-C6, neurological emergencies-C7, trauma-C8*)
7.3. approach to healthy individual or patient (*fever-C1, cardiovascular disease-C2, chest pain-C2, cough and hemoptysis-C2, dyspnea-C2, anemia-C3, lymphadenopathy-C3, diarrhea-C4, pregnancy-C5, urinary tract infection-C6, neurological symptoms-C7, headache-C7, depression-C7, dementia-C7, musculoskeletal dysfunction-C8*)
7.4. laboratory and imaging tests/examinations
7.4.1. based on laboratory disciplines/subdisciplines;
1. medical biochemistry tests:
i. *(venous blood collection-C5*)
ii. *(thyroid function tests-C5, diabetes tests-C5)*
2. medical microbiology tests:
i. *(urine sample collection-C1, throat swab specimen-C5, sputum sample collection-C5, urethral-vaginal-cervical discharge/swab specimen-C6, fecal specimen collection-C6, wound sample collection-,blood collection for culture-*)
ii. *(urine strip/dipstick test-C1, urine culture-C1, rapid screening (antigen/antibody) tests-C5, throat culture-C5, sputum culture-C5, urethral-vaginal-cervical discharge culture-C6, fecal culture-C6, wound culture-, blood culture-)*
3. medical pathology tests:
i. *(C2, C4, C6, C7, C8, Pap smear collection)*
ii. *(C2, C4, C6, C7, C8, Pap smear)*

4. other laboratory tests:
i. *(peripheral/venous blood collection for hematology tests-C3, blood sample collection for therapeutic drug monitoring-C8)*
ii. *(pulmonary function tests-C2, hematology tests for anemia-C3, monitarization of drug therapy-C8)*

5. radiological examinations: *(radiological examinations in gynecology-C5, breast imaging-C5, uroradiology-C6, conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8)*
6. nuclear medicine examinations: *(nuclear medicine tests in infectious diseases-C1, radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac PET-C2, ventilation/perfusion scintigraphyi-C2, PET in lung cancer-C2, nuclear medicine tests in hematology-C3, scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumors-C4, radioisotope imaging of thyroid and parathyroid-C5, renal scintigrahy (GFR, ERPF, Renogram)-C6, brain perfusion scintigraphy-C7, brain PET-C7, bone scintigraphy-C8)*

7.4.3. point of care testing
a. based on laboratory disciplines/subdisciplines;
1. medical biochemistry tests: *(diabetes tests-C5, cardiac markers-, coagulation tests-, blood gases-).*
2. medical microbiology tests: *(urine strip/dipstick test-C1, rapid screening (antigen/antibody tests-C5)*
3. other laboratory testsi: *(hematology-peripheral blood smear examination-C3, hematology-complete blood count-)*

7.5. making preliminary diagnosis or definitive diagnosis decision
7.6. making non-intervention or intervention decision
7.7. practicing non-intervention or intervention
7.8. referral/transport of healthy individual or patient

INTRODUCTION TO CLINICAL SCIENCES (MED 302)

AIMS

In evidence based manner:

1. ***to remind*** anatomy, histology and physiology of body systems,
2. ***to convey*** necessary knowledge, related to body systems, on prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions.
3. at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;

3.1. ***to convey*** necessary knowledge on risk factors, etiopathogenesis, physiopathology, and pathology,
3.2. ***to convey*** knowledge on epidemiology,
3.3. ***to convey*** knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
3.4. ***to convey*** necessary knowledge on health care processes, clinical decision making process, clinical decisions and clinical practices, with performance measures, for managing at the level of 7primary health care service,

4. ***to convey*** knowledge on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
5. ***to convey*** knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
6. ***to convey*** knowledge on biostatistical analysis,
7. ***to convey*** basic legal and ethical principles that should be followed in practice of medical profession,

LEARNING OBJECTIVES

At the end of this phase, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of body systems.
2.0. ***list*** necessities for prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions in relation to body systems.
3.0. ***explain*** risk factors and etiopathogenesis, at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
4.0. at cellular or tissue level,
4.1. ***recognize*** morphological characteristics,
4.2. ***show*** basic pathological changes that occur in clinical conditions.
5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
5.1. ***explain*** mechanisms of destruction at molecule, cell, tisssue, organ, system, multi-system and organismal level,
5.2. ***describe*** structural and functional changes caused,
5.3. ***list*** clinical courses in time.
6.0. ***explain*** mechanisms of emergence for frequently encountered;
6.1. clinical complaints,
6.2. symptoms,
6.3. signs,
6.4. laboratory and imaging findings

of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
7.0. at multi-system level or related to a body system,

- for healthy conditions in an individual or community with a request, or
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes,
- acquisition of subjective or objective data, information and knowledge required for clinical decision making,
- clinical decision making process,
- clinical decisions and

• clinical practices
which are required for management at primary health care service level.
7.1. evaluation of emergency case (*sepsis and septic shock-C1, dyspnea-C2, acute abdominal pain-C4, urological emergencies-C6, neurological emergencies-C7, trauma-C8*)
7.2. approach to healthy individual or patient (*fever-C1, cardiovascular disease-C2, chest pain-C2, cough and hemoptysis-C2, dyspnea-C2, anemia-C3, lymphadenopathy-C3, diarrhea-C4, pregnancy-C5, urinary tract infection-C6, neurological symptoms-C7, headache-C7, depression-C7, dementia-C7, musculoskeletal dysfunction-C8*)
7.3. laboratory and imaging tests/examinations
7.3.1. based on laboratory disciplines/subdisciplines;
1. medical biochemistry tests:
i. *(venous blood collection-C5*)
ii. *(thyroid function tests-C5, diabetes tests-C5)*
2. medical microbiology tests:
i. *(urine sample collection-C1, throat swab specimen-C5, sputum sample collection-C5, urethral-vaginal-cervical discharge/swab specimen-C6, fecal specimen collection-C6, wound sample collection-,blood collection for culture-*)
ii. *(urine strip/dipstick test-C1, urine culture-C1, rapid screening (antigen/antibody) tests-C5, throat culture-C5, sputum culture-C5, urethral-vaginal-cervical discharge culture-C6, fecal culture-C6, wound culture-, blood culture-)*
3. medical pathology tests:
i. *(C2, C4, C6, C7, C8, Pap smear collection)*
ii. *(C2, C4, C6, C7, C8, Pap smear)*

4. other laboratory tests:
i. *(peripheral/venous blood collection for hematology tests-C3, blood sample collection for therapeutic drug monitoring-C8)*
ii. *(pulmonary function tests-C2, hematology tests for anemia-C3, monitarization of drug therapy-C8)*

7.3.2. imaging tests/examinations based on disciplines/subdisciplines:
1. radiological examinations: *(radiological examinations in gynecology-C5, breast imaging-C5, uroradiology-C6, conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8)*
2. nuclear medicine examinations: *(nuclear medicine tests in infectious diseases-C1, radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac PET-C2, ventilation/perfusion scintigraphyi-C2, PET in lung cancer-C2, nuclear medicine tests in hematology-C3, scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumors-C4, radioisotope imaging of thyroid and parathyroid-C5, renal scintigrahy (GFR, ERPF, Renogram)-C6, brain perfusion scintigraphy-C7, brain PET-C7, bone scintigraphy-C8)*

7.3.3. point of care testing
a. based on laboratory disciplines/subdisciplines;
1. medical biochemistry tests: *(diabetes tests-C5, cardiac markers-, coagulation tests-, blood gases-).*
2. medical microbiology tests: *(urine strip/dipstick test-C1, rapid screening (antigen/antibody tests-C5)*
3. other laboratory testsi: *(hematology-peripheral blood smear examination-C3, hematology-complete blood count-)*

7.5. making preliminary diagnosis or definitive diagnosis decision
7.6. making non-intervention or intervention decision
7.7. referral/transport of healthy individual or patient

INTRODUCTION to CLINICAL PRACTICE- III (MED 303)

Aim

This course aims to equip the students with basic medical skills such as history taking regarding to systems and in general, physical and mental examination in simulated environments in pre-clinical period and to give the students opportunity to develop skills by applying non –invasive or invasive procedures on the mannequins before encountering with real patients. The students improve the gained skills by observing real encounters in the clinical settings during 2nd and 3rd year.

Learning Objectives

Description

ICP is a three year longitudinal course that aims to introduce students to the concepts and main elements of medical practice. It will also be an introduction to the medical profession as a whole and will provide a foundation for clinical practice. The course provides knowledge, cognitive and motor skills and experience in fundamental processes and aspects of medical practice. It involves the application of scientific theory, quality assurance and evidence-based best practice protocols.

Credit Facility:

This course has 5 ECTS credits for the first and third year students while it is 4 ECTS for the second year students and all of the students are required to pass this course in order to pass the year.

Content of the ICP I-II-III

First year medical students gain knowledge on First Aid approaches, develop skills in Basic Life Support, Patient/Casualty Transportation and Bandaging Techniques regarding to First Aid. They also acquire basic knowledge on communication and experience patient-doctor encounter with simulated patients (SP's).

The second years ICP Program consist of modules like handwashing, wearing sterile gloves, assessing vital signs, nasogastric intubation, bladder catheterization, intramuscular, subcutaneous, intradermal and intravenous injections as well as iv. catheterization.

In the third year medical students practice with SP's clinical skills like history taking and physical examination focused on body systems and in general and also mental examination. They also gain clinical skills such as suturing techniques and Advanced Cardiac Life Support.

Clinical Skills Laboratory

The Clinical Skills Laboratory is designed for teaching and assessing students at undergraduate level (during the preclinical period from first-year to third year). The lab provides learners with the ideal setting to practice the clinical skills of history taking, physical examination, communication, and gives opportunities to practice invasive and non invasive procedural skills on mannequins.

Each exam room is equipped with video cameras and microphones to record the encounter. An observation area at the center of the lab allows faculty and students to observe the encounters live or view digital recordings for subsequent analysis.

Simulated Patients (SPs)

The simulated patient encounters provide transition of students from the classroom to standardized patient contact in safe environments.

Encounters with specially trained individuals, known as simulated patients (SPs), simulate specific cases in outpatient and emergency settings. The pool of SPs consist of adults, from various backgrounds.

Clinical cases are created through research and extensive training of the patients portraying these roles.

Assessment: The Assessment procedure of ICP is given in Assessment Table in this booklet.

Rules for Attendance of the Students: Students are grouped into 4 and group lists are announced in the announcement board at the beginning of the year. Any changes to practical groups on a week by week basis, will only be considered in exceptional situations such as a medical one. Any changes must be requested by a petition along with relevant documentation to the course coordinator. Any change in sessions will only be accepted interchangeably with another student in another group based on availability of work spaces and course coordinator's discretion (based on evidence provided).
Students are required to follow the rules of professional ethics in the laboratory at any time.

When an OSCE is conducted both students and faculty members complete a written evaluation of the event for the improvement of the course and OSCE.

SPECIFIC SESSIONS / PANELS

Introductory Session

Aim of the session:
The session provides basic information about Yeditepe University Faculty of Medicine Undergraduate Medical Education Program (YUFM/UG-ME) and the educational phase relevant to the students. This session orients the students to the program and the phase.

Objectives of the Session:
1. To provide basic information about the YUFM/UG-ME.
2. To provide basic information about the phase.
3. To provide essential information on social programs and facilities.

Rules of the Session:
1. The session will be held in two types, conducted by Phase Coordinator and Committee Coordinator, respectively.
2. The first type will be held once in the first week of the educational phase. The second type will be held at the beginning of each committee.
3. Students should attend the session.

Implementation of the Session:
In the first type, Phase Coordinator will present brief information on the following topics:
- Organizational Chart of Yeditepe University Faculty of Medicine Undergraduate Program (YUFM/UG-ME), Work Descriptions and Introduction of Committees Members,
- Directives on YUFM/UG-ME,
- YUFM/UG-ME Program Outcomes
- Learning Objectives of the Phase
- Academic Program of the Phase
- Teaching and Learning Methods
- Learning Environments and Sources/Resources
- Attendance
- Elective Courses (only in Phase I and Phase II)
- Assessment Procedure
- Grade Point Average, Cumulative Grade Point Average (GPA, cGPA) Calculation
- Pass/Fail Conditions
- Feedback of the Previous Year and Program Improvements
- Social Programs and Facilities

In the second type, Committee Coordinator will present brief information on the following topics:
- Learning Objectives of the Committee
- Academic Program of the Committee
- Teaching and Learning Methods
- Learning Environments and Sources/Resources, References
- Attendance
- Assessment Methods and Question Distribution Table
- Committee Score Calculation Method
- Pass/Fail Conditions
- Feedback of the Previous Year and Program Improvements
- Social Programs and Facilities

Committee Evaluation Session

Aim of the Session:

The aim of the session is to evaluate the committee educational program, with all its components, by the students and the committee coordinators. This session will contribute to the improvement of the educational program in general by giving the opportunity to identify the strengths of the committee educational program and revealing the areas which need improvement.

Objectives of the Program Evaluation Session are to;

- establish a platform for oral feedbacks in addition to the systematically written feedback forms
- give the opportunity to the students and the coordinators to discuss the committee period face to face
- allow the students to review the committee exam questions together with faculty members.

Process:

The total duration of the session is 90 minutes and the session consists of two parts. The first part (30 minutes) is dedicated to oral feedback by the students. All of the oral feedback will be recorded and reported by the committee coordination team. In the second part (60 minutes) committee exam questions will be reviewed and discussed by students and faculty.

Rules of the Committee Evaluation Session :

1. The **Committee Evaluation Session** will be held on the last day of each committee after the committee exam.
2. Students are required to attend the session.
3. The Committee coordinator will lead the session.
4. The faculty members who had contributed questions in the committee exam should attend the session.
5. Students must comply with the feedback rules while giving verbal feedback and all participants shall abide by rules of professional ethics.

Committee Improvement Session

Aim:

The aim of this session is sharing the program improvements based on the evaluation of the educational program data, with the students and the faculty members.

Objectives:

1. To share the improvements within educational program with the students and the faculty members.
2. To inform the students and the faculty members about the processes of the program improvement
3. To encourage student participation in the program improvement processes.

Rules:

1. Program improvements session will be implemented once a year. The implementation will be performed at the begining of the spring semester.
2. Students are required to attend the session.
3. The phase coordinator will monitor the session. If necessary the dean, vice deans and heads of the educational boards will attend to the session.
4. All faculty members will be invited to the session.

Implementation:

Before the Session

1. Phase coordinator will report the results of the improvements of the educational program.
2. The program improvements report has three parts. The first part of the report includes improvements that have been completed, and those that are currently in progress. The second part of the report includes, improvements that are planned in medium term, and the third part of the report includes, improvements that are planned in the long term.
3. The program improvements report also includes the program evaluation data (student feedbacks, faculty feedbacks, results of the educational boards meetings etc.) in use of improvements.

During the Session

4. The phase coordinator will present the program improvements report to the students and the faculty members.
5. Students can ask questions about, and discuss, the results of the program improvement.

Process: The total period of session is 30 minutes and has two parts. The first part (15 minutes) covers, presenting of the program improvement report. The second part (15 minutes) covers, students' questions and discussion.

After the Session

6. The program improvement brief will be published on the website of Yeditepe University Faculty of Medicine (http://med.yeditepe.edu.tr).

Multidisciplinary Case Discussion Panel

Aim:
The aim of this instructional method is, to integrate what students learnt during committee, to fit in the clinical context and to promote deep learning.

Objectives:
1. To relate learning objectives of the committee,
2. To relate clinical cases and learning subjects,
3. To explain learning objectives in the resolution of clinical cases,
4. To value the importantance of multidisiplinary study in the resolution of clinical cases.

Implementation:
Before the Panel
1. Case/cases that will be discussed in the panel will be chosen by a multidisiplinary team, in compliance with committee learning objectives.
2. The resources to analyse the cases will be specified by multidisiplinary team.
3. Students can get hard copies of the cases and the list of sources from student affairs at the beginning of the committee.
4. Students shall study cases in the context of learning objectives before the panel.
5. Before the panel, students may consult the faculty members for information about cases.

During the Panel
6. Cases will be shared visually with students by the multidisiplinary team.
7. Possible resolution of cases will be shared and discussed with students by the multidisiplinary team.
8. After the resolution of cases, students can ask questions to faculty members about the commitee learning obcetives in the context of cases.

Process: The total duration of the Panel is 60 minutes and has 2 parts. The first part (40 minutes), covers the presentation of cases, resolution of cases, asking questions to students and discussion as suitable to learning objectives during the resolution by multidisiplinary team. The second part (20 minutes), covers students' questions and discussion.

After the Panel
9. Students may continue reviewing the cases in the context of committee learning objectives.
10. The multidisiplinary team will review the usefulness of cases as a learning tool in the context of committee learning objectives. "The Panel Report" will be written by the multidisiplinary team.

INDEPENDENT LEARNING

Description:
"Independent learning" is a process, a method and a philosophy of education in which a student acquires knowledge by his or her own efforts and develops the ability for inquiry and critical evaluation. It includes freedom of choice in determining one's learning objectives, within the limits of a given project or program and with the aid of a faculty adviser. It requires freedom of process to carry out the objectives, and it places increased educational responsibility on the student for the achieving of objectives and for the value of the goals (1).

Aim:
The aim of this instructional strategy is to develop the students' ability, to learn individually, so they are prepared for the classroom lessons, lectures, laboratory experiences and clinical practices, exams, professional life and have the abilities needed for lifelong learning.

Objectives:
With this instructional strategy, students will develop;

- the skills that will help them to learn independently.
- self-discipline in their work habits.
- their evidence based research skills by using reliable resources.
- their teamwork skills by studying together.
- their clinical skills as self-directed working in the clinical skills laboratory.

Rules:
1. All of the students will define independent learning process according to below algorithm.
2. All of the students will be required to fill out a form, which is a self-assessment form for the independent learning (methodology: timing, sources, strategy, etc.).
3. The students' academic performance and independent learning methodology will be analyzed comparatively, and feed-back on further improvements will be provided.

What a student should do for learning independently?
1. **Analyzing:** First you will need to analyze carefully, what your problems and weaknesses are. For example, if you are studying anatomy, is your weak area broadly upper limb, lower limb, or what?
2. **Addressing:** Once you've decided your specific problems, you can list them. Which one needs to be addressed urgently? Work out your priorities. Whatever your subject area is, don't be afraid to return to the basics if necessary. It may give you more confidence in the long run to ensure you have a proper understanding of basic concepts and techniques.
3. **Accessing:** If you need reliable information, or if you need to read about a subject and put it into context, a textbook may be the best place to start. However, the Internet may be helpful if you need very up-to-date information, specific facts, or an image or video etc. If you need an academic research article, reports or case studies for your topic, then a database (Pubmed etc.) would be the best option.
4. **Timing:** In the weekly syllabus you will see, a specific time called "independent learning hour" for your independent work. In addition to these hours, the students should also have their own time schedule for their study time at home.
5. **Planning:** Your next step will be to work out a realistic study-plan for your work. What goals could you literally set for yourself? Don't make them too ambitious but set minor goals or targets that you know you will be able to achieve without having to spend a very long time working on them. How many hours will you need to achieve them? How will you know when you've achieved them?
6. **Recording:** When you work independently, it's a good idea to keep a written record of the work you've done. This can help with further planning and also give a sense of achievement as well as provide something to include in a progress file. As time goes by you may surprise yourself with what you've been able to achieve. This could motivate you to keep going, as could increase your confidence, and even improve your results
7. **Reflecting:** Reflecting on what you've done can help you decide whether the activity was really effective, whether an alternative approach might be better on another occasion, whether you spent the right amount of time and whether you have achieved the target you'd set yourself.
8. **Improving:** Once you've achieved the target, the process of planning can start again. Your needs and priorities may have changed, so think about them and then set yourself to another target.

Reminder: For further information about the independent learning, please contact the Department of Medical Education.

Reference:

1. Candy, P. (1991) Self-direction for lifelong learning: a comprehensive guide to theory and practice. San Francisco: Jossey Bass.

For further reading useful resources to recommend to students:

- Burnapp, D. (2009). Getting Ahead as an International Student. London: Open University Press.
- Marshall, L. & Rowland, F. (1998) A Guide to learning independently. London: Open University Press.
- University of Southampton / UKCISA online resource 'Prepare for Success'

ASSESSMENT PROCEDURE

The Assessment Procedure of the Phase III covers exams and scores and their abbrevations that shown below.

- Exams:
  - Committee Exam (CE)
  - Mid-term Exam (MTE)
  - Final Exam (FE)
  - Incomplete Exam (ICE)
  - Make-up Exams (MUE)
- Scores*:
  - Committee Score (CS)
  - Committees Mean Score (CMS)
  - Introduction to Clinical Practice Score (ICPS)
  - Scientific Project Score (SPS)
  - Final Exam Score (FES)
  - Incomplete Exam Score (ICES)
  - Term Score (TS)

* All scores have a range of 0-100 points.

Assessment approaches, assessment methods and assessment tools, that related with the exam and score types, are shown in below table.

Assessment Approaches	Assessment Methods	Question Types / Assessment Tools	Exams	Derived Scores
Knowledge-based Assessment	WE: Written Examination	MCQ: Multiple Choice Questions	CE, MTE, FE, ICE	CS, ICPS, FES, ICES
		EMQ: Extended Matching Questions	CE	CS
		FSAQ: Fill-in-the-Blank Short Answer Questions	MuE	CS
Competency–based Assessment	OSCE: Objective Structured Clinical Examination	OSCE Checklist		ICPS
Performance–based Assessment	PWPE: Project Writing and Presenting Evaluation	PWPE Checklist		SPS

Exams Information (MED 302, MED 303)	
CE	For the proportional correspondence of individual learning objectives, please see the committee's assessment matrix table/page.
FE	FE consists of 200 MCQs. For the proportional contribution of each committee, please see the committee's assessment matrix table/page.
ICE	ICE consists of 200 MCQs. For the proportional contribution of each committee, please see the committee's assessment matrix table/page.
MUE$_{ICS}$	MUE will be held only twice in a term. MUE consists of FSAQs. MUE content will be developed by the coordination committees.

Scores Information (MED 302, MED 303)	
CS	The committee score is based on various question types/numbers and/or assessment tools (MCQ, EMQ, MEQ or Checklists). Please see the committee's assessment matrix table/page for the specifications.
CMS	= Average of CSs
ICPS	= (50% OSCE1) + (50% OSCE2)
SPS	= Score information is shown in below Scientific Projects Assessment Table.
FES	= Final Exam Score
ICES	= Incomplete Exam Score
TS *for students, who are exempted from FE*	= 96% of CMS + 4% of SPS
TS *for students, who are not exempted from FE*	= 96% of (60% of CMS + 40% of FES or ICES) + 4% of SPS

Pass or Fail Calculations of the Courses
Introduction to Clinical Sciences (ICS) III (MED 302)
Pass; *TS* **≥ *50***
Fail; *FES* **< *50*** *(barrier point), ICES* **< *50*** *(barrier point), or/and TS* **< *50***
The student is exempted from FE, if the CMS is **≥ *75*** *and all CSs are* **≥ *50***
The FE and ICE barrier point is not applied to the students whose all CSs are **≥ *50***
Introduction to Clinical Practise (ICP) III (MED 303)
Pass; *ICPS* **≥ *50***
Fail; *ICPS* **< *50***

The Assessment Procedure of the Phase III will be announced and explained in the introductory session at the beginning of the academic year.

Definitions of the Assessment Methods and Question Types

MCQ consist of a question, followed by five plausible alternative responses from which the student has to select the correct one.

EMQ are similar to multiple choice questions but with one key difference, that they test knowledge in a far more applied, in depth, sense. EMQ is based on a single theme, two or more questions and has a long option list.

MEQ is made up of one or more short answer questions. The student is provided with basic science or clinical information and then asked to write brief responses to one or more questions. When a series of questions is presented, additional information about the original problem can be provided at each subsequent step, guiding the students through an analytical process.

FSAQ, Fill-in-the-Blank Short Answer Questions are typically composed of a brief prompt that demands a written answer that varies in length from one or two words to a sentence.

OSCE describes a form of competency-based testing used to measure a student's clinical competence. During an OSCE, students are observed and evaluated as they go through a series of stations in which they interview, examine and treat simulated patients who present with some type of medical problem.

SCIENTIFIC PROJECTS – III

The purpose of Scientific Projects class is to teach the medical students how to run and complete a scientific project. Throughout the year, each Phase Three student is expected to realize their scientific project proposal presented during Phase II. Students who wish to apply for a "TUBITAK 2209-A National Grant Program for University Students" has to send in their final proposals before February 2018. The rest should hand in their proposal drafts during the small group studies which will be held in parallel with ICP hours. Please see the progam. The students lists for small group studies will be announced during the first week of educational year. All projects will be presented as posters at Scientific Day of Yeditepe School of Medicine, during May, 2018. Scientific Projects course has 4% contribution to Term Score (TS).

Please note that it is mandatory to attend to Small Group Study hours in the assigned group hours. A list of groups will be published during the first week of the term.

CRITERIA	**Unsatisfactory**	**Below Expectations**	**Meets Expectations**	**Above Expectations**	**Clearly Outstanding**	**Not Addressed / Observed**
Is the question/ problem presented clearly?	1	2	3	4	5	0
Creativity/originality of the Project	1	2	3	4	5	0
Project presentation in correct format	1	2	3	4	5	0
Presentation of aims/results/conclusion in an easy to understand format	1	2	3	4	5	0
Results and their interpretation clearly presented (graphics, statistics)	1	2	3	4	5	0
Does project explain the significance of results and their impact well?	1	2	3	4	5	0
Is result/conclusion clearly presented?	1	2	3	4	5	0
Correct writing of terminology and references	1	2	3	4	5	0
TOTAL POINTS	**40 x 2,5=100 pts (if all criteria has 5 points)**					

EXAM RULES

- **Seating-** Students will be seated by the exam observers or proctors. Students are not allowed to change their seats without permission.
- **Electronics** – During examinations or tests, students are prohibited from using electronic devices or any other means of communication and recording that have not been approved beforehand. All electronic devices are prohibited. Anyone who fails to comply with these regulations may be charged with academic fraud.
- **Absence** – No additional time will be given to students who are absent for part of the exam, regardless of the reason for their absence.
- **Scratch Paper** – Students are not allowed to bring scratch paper into the exam room.
- **Meaning of Questions** – Students may not consult the supervisor as to the meaning of any question.
- **Signature** – Students must sign their multiple-choice answer sheets and/or written-answer sheets.

- **Other activities requiring disciplinary action**-
    - Students must not give or receive Asstance of any kind during the exam.
    - Gaining access to exam questions before the exam.
    - Using an unauthorized calculator or other mechanical aid that is not permitted.
    - Looking in the exam book before the signal to begin is given.
    - Marking or otherwise writing on the exam book or answer sheet before the signal to begin is given.
    - Making any changes, additions, deletions or other marking, erasing or writing on the exam book or answer sheet after the time for the exam has expired.
    - Having access to or consulting notes or books during the exam.
    - Looking at or copying from another student's paper.
    - Enabling another student to copy from one's paper.
    - Talking or otherwise communicating with another student during the exam or during the read through period.
    - Disturbing other students during the exam.
    - Consulting other persons or resources outside the exam room during the exam.
    - Copying questions or answers either on paper or with an electronic device to take from the exam room.
    - Taking an exam book or other exam materials from the exam room.
    - Taking an exam in place of another student.
    - Arranging to have another person take an exam for the student.
    - Disobeying to the conduct of supervisor during the exam.
    - Disclosing the contents of an exam to any other person.
    - Failing to remain in the exam room for a given period of time by the supervisors.
    - Failing to follow other exam instructions.

Those students found to have committed academic misconduct will face administrative sanctions imposed by the administration of Yeditepe University Faculty of Medicine according to the disciplinary rules and regulations of the Turkish Higher Education Council (YÖK) for students (published in the Official Journal on August 18th, 2012). The standard administrative sanctions include, the creation of a disciplinary record which will be checked by graduate and professional life, result in grade "F" on the assignment, exams or tests or in the class. Students may face suspension and dismissal from the Yeditepe University **for up to one school year**. In addition, student may loose any academic and non academic scholarships given by the Yeditepe University **for up to four years**. The appropriate sanctions are determined by the Yeditepe University administration according to egregiousness of the Policy violation.

COURSE LOCATIONS

COURSE CODES	COURSE NAMES	LOCATIONS
MED 302	Introduction to Clinical Sciences	**Lectures/Sessions/Panels:** Room Number: B309, Base Floor, Medical Faculty Block, Yeditepe University Campus. **Microbiology Laboratory:** Room Number: 934, 5th Floor, Medical Faculty Block, Yeditepe University Campus. **Pathology Laboratory:** Room Number: 929-930, 5th Floor, Medical Faculty Block, Yeditepe University Campus.
MED 303	Introduction to Clinical Practice	**ICP-CSL:** Room Number: 442, Base Floor, Medical Faculty Block, Yeditepe University Campus. **YH:** Yeditepe University Hospital.

Yeditepe University Campus Address: İnönü Mah. Kayışdağı Cad. 26 Ağustos Yerleşimi, 34755, Ataşehir, İstanbul.

Yeditepe University Hospital Address: İçerenköy Mah. Hastane Yolu Sok. No:102-104. Ataşehir, İstanbul.

ACADEMIC CALENDAR of PHASE III 2017 - 2018

COMMITTEE I
INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEMS (8 Weeks)

Beginning of Committee	September 06, 2017	Wednesday
End of Committee	October 27, 2017	Friday
Committee Exam	**October 27, 2017**	**Friday**

COMMITTEE II
CARDIOLOGY AND RESPIRATORY SYSTEM (7 Weeks)

Beginning of Committee	October 30, 2017	Monday
End of Committee	December 15, 2017	Friday
Committee Exam	**December 15, 2017**	**Friday**
National Holiday	**October 28$^{1/2}$, 2017**	**Saturday**
Commemoration of Atatürk	**November 10, 2017**	**Friday**

COMMITTEE III
GASTROINTESTINAL SYSTEM (4 Weeks)

Beginning of Committee	December 18, 2017	Monday
End of Committee	January 12, 2018	Friday
Committee Exam	**January 12, 2018**	**Friday**
New Year	**January 01, 2017**	**Monday**
MIDTERM BREAK	**January 15 - 26, 2018**	**Monday - Friday**

COMMITTEE IV
ENDOCRINE, REPRODUCTIVE AND URINARY SYSTEM (8 Weeks)

Beginning of Committee	January 29, 2018	Monday
End of Committee	March 23, 2018	Friday
OSCE I (Exam)	**February 27-28, 2018**	**Tuesday-Wednesday**
Committee Exam	**March 23, 2018**	**Friday**
Make-up Exam I (ICS)	**February 2, 2018**	**Friday**

COMMITTEE V
NERVOUS SYSTEM and PSYCHIATRY (6 Weeks)

Beginning of Committee	March 26, 2018	Monday
End of Committee	May 4, 2018	Friday
Committee Exam	May 4, 2018	**Friday**
ICP Make-up Exam	**April 27, 2018**	**Friday**
Physicians' Day	**March 14, 2018**	**Wednesday**

COMMITTEE VI
MUSCULOSKELETAL SYSTEM (4 Weeks)

Beginning of Committee	May 7, 2018	Monday
End of Committee	June 1, 2018	Friday
Committee Exam	June 1, 2018	**Friday**
National Holiday	**April 23, 2018**	**Monday**
Labour's Day	**May 01, 2018**	**Tuesday**
OSCE II (Exam)	**June 6-7, 2018**	**Wednesday - Thursday**
Make-up Exam II (ICS)	**June 15, 2018**	**Friday**
National Holiday	**May 19, 2018**	**Saturday**
Final Exam	**June 22, 2018**	**Wednesday**
Incomplete Exam (ICP)	**July 9, 2018**	**Monday**
Incomplete Exam (ICS)	**July 13, 2018**	**Friday**
Religious Holiday	**June $14^{1/2}$ – 17, 2018**	**Thursday-Sunday**
1. Coordination Committee Meeting	October 18, 2017	**Wednesday**
2. Coordination Committee Meeting	January 10, 2018	**Wednesday (with student participation)**
3. Coordination Committee Meeting	May 9, 2018	**Wednesday (with student participation)**
4. Coordination Committee Meeting	July 04, 2018	**Wednesday**

RECOMMENDED TEXTBOOKS

Biomedical Ethics & Deontology

1. Marcia Lewis, Carol D. Tamparo. Medical Law, Ethics, & Bioethics for the Health Professions, F.A. Davis Publishing House, 2012, ISBN: 0803627068
2. Michael Boylan. Medical Ethics, Wiley-Blackwell Publishing House, 2013, ISBN: 978-1118494752

Biostatistics

1. Pagano, Marcello, Gauvreau, Kimberlee. Principles of Biostatistics. Duxbury Press, 2000 ISBN 0534229026, 9780534229023.
2. Glantz, Stanton A. Primer of Biostatistics. 7th Edition. McGraw Hill Professional, 2011. ISBN 0071447814, 9780071447812.

Infectious Diseases and Clinical Microbiology

1. Murray, Patrick R, Rosenthal, Ken S, Pfaller, Michael A.. Medical Microbiology with STUDENT CONSULT Online Access. 7th Edition, 2012, ISBN-10: 0323086926, ISBN-13: 978-0323086929.

Medical Genetics

1. Turnpenny, Peter D, Ellard, Sian. Emery's Elements of Medical Genetics. 14th Edition. Churchill Livingstone, 2012, ISBN: 9780702040436

Neurosurgery

1. Microneurosurgery, Volume I to Volume V, Thieme Kindle Edition by Mahmut Gazi Yasargil (Author)
2. Neurology and Neurosurgery Illustrated, 5th Edition by Kenneth W. Lindsay PhD FRCS (Author), Ian Bone FRCP FACP (Author), Geraint Fuller MD FRCP (Author)
3. Handbook of Neurosurgery Feb 22, 2010 by Mark S. Greenberg

Pharmacology

1. Harvey, Richard A. Lippincott's Illustrated Review of Pharmacology. 6th ed., Wolters Kluwer Health, 2015. ISBN-13: 978-1-4698-8756-2; ISBN-10: 1-4698-8756-8
2. Katzung, Bertram G., Masters, Susan B., Trevor Anthony J. Katzung's Basic & Clinical Pharmacology. 13th Edition. McGraw Hill Companies, 2015. ISBN-13: 978-0071825054
ISBN-10: 0071825053
3. Brunton, Laurence, Chabner, Bruce, Knollman, Bjorn. Goodman&Gilman's The Pharmacological Basis of Therapeutics. Editors: 12th Edition. McGraw Hill Companies, 2011. ISBN-13: 978-0071624428

Orthopedic Surgery

1. Ortopedik Fizik Muayane, çeviri ed. Uğur Şaylı, Güneş Tıp Kitapevi
2. Review of Orthopaedics, 6th edition (ed. Mark D. Miller)
3. AAOS Comprehensive Orthopaedic Review, 2nd edition (ed. Martin I. Boyer)

Pathology

1. Abbas Aster, Kumar. Robbıns Basıc Pathology. 9th edition, Saunders, Elsevıer Inc. 2013. ISBN:978-0-8089-2432-6

Psychiatry

1. Öztürk O. Ruh Sağlığı ve Bozuklukları. 2. Baskı, Ankara 2011. ISBN: 9786058617292
2. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 9. Ed. 2009, Lippincott Williams & Wilkins, PA, USA. ISBN: 9780781768993
3. Purves D, Augustine GJ. Fitzpatrick D. et al. Neuroscience. 5. Ed. 2012, Sinauer Assoc, Mass, USA. ISBN: 9780878936953

General Surgery

1. Brunicardi, F. Schwartz's Principles of Surgery, 10th edition, July 16, 2014, ISBN: 0071796754 / 9780071796750

Urology

1. Campbell-Walsh Urology, 11th Edition 4-Volume Set. By Alan J. Wein, MD, FACS, PhD (hon), Louis R. Kavoussi, MD, Alan W. Partin, MD, PhD and Craig A. Peters, MD, FACS, FAAP. Imprint: Elsevier. ISBN: 978-1-4557-7567-5. Copyright: 2016

COMMITTEES

In Phase I, II and III, the formation of committees is based on a thematic structure. This structure corresponds to organizational levels of human body such that macromolecule, organelle, cell, tissue, organ systems and finally introduction to pathogenesis.

- Phase I: Normal structure and function of human body at molecular, cellular, tissue and organ level.
- Phase II: Normal structure and function of human body at system and multi-system level, and introduction to pathogenesis.
- Phase III: Physiopathological and pathological processes in human body.

Besides this thematic structure, there is a continuous clinical skills education in Phase I, II and III, as “Introduction to Clinical Practice -I, -II and -III” courses.

Therefore, the core medical courses are;

- Phase I: MED 104 Basic Medical Sciences I, MED 102 Introduction to Clinical Practice I, MED 103 Anatomical Drawing,
- Phase II: MED 201 Basic Medical Sciences II, MED 202 Introduction to Clinical Practice II,
- Phase III: MED 302 Introduction to Clinical Sciences, MED 303 Introduction to Clinical Practice III.

The learning objectives of the phase include learning objectives of core courses. The learning objectives of committees include learning objectives of core courses’ components for the committee.

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM

DISTRIBUTION of LECTURE HOURS

September 06, 2017 - October 27, 2017

COMMITTEE DURATION: 8 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	INFECTIOUS DISEASES AND MEDICAL MICROBIOLOGY	IDCM	27		2 (4 Groups)		**27**
	PHARMACOLOGY	PC	22				**22**
	PATHOLOGY	PT	12			2	**14**
	PUBLIC HEALTH	PH	8				**8**
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	10				**10**
	HEMATOLOGY	HEM	9				**9**
	BIOSTATISTICS	BS	3				**3**
	IMMUNOLOGY	IMM	6				**6**
	PATHOPHYSIOLOGY	PP	4				**4**
	FAMILY MEDICINE	FM	2				**2**
	MEDICAL GENETICS	MG	5				**5**
	EMERGENCY MEDICINE	EM	1				**1**
	PEDIATRICS	PED	5				**5**
	PHYTOTHERAPY	PHY	3				**3**
	ONCOLOGY	ONC	3				**3**
	RADIATION ONCOLOGY	RONC	2				**2**
	SCIENTIFIC PROJECTS-III	SP	2				**2**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			2 X 3=6 (4 Groups)		**6**
TOTAL			**124**		**6**	**4**	**134**

Coordination Committee

HEAD	Meral Sönmezoğlu, MD, Prof.
SECRETARY	Orhan Önder Eren, MD, Asst. Prof
MEMBER	A. Çağrı Büke, MD, Prof.
MEMBER	Ayşegül Kuşkucu, MD, Asst. Prof.
MEMBER	Atilla Özkan, MD, Assoc. Prof

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
INFECTIOUS DISEASES AND MEDICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof. Çağrı Büke, MD, Prof. İ. Çağatay Acuner, MD, Assoc. Prof. Barış Ata Borsa, Asst. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Zafer Gören, MD, Prof. Feyza Arıcıoğlu, PhD, Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD, Prof.
HEMATOLOGY	Atilla Özkan, MD, Assoc.Prof.
PEDIATRICS	Sabri Kemahlı, MD, Prof. Hülya Sarıçoban, MD, Assoc. Prof. Sema Yılmaz, MD, Assoc. Prof./ S. Perihan Saf, MD
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof. Hale Arık Taşyıkan, MD, Asst. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Hakan Ertin, MD, Assoc. Prof. Rainer Brömer, PhD, Assoc. Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Assoc.Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Asst Prof.
BIOISTATISTICS	Çiğdem Altunok, PhD, Asst. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
PHYTOTHERAPY	Erdem Yeşilada, PhD, Prof.
ONCOLOGY	Orhan Önder Eren, MD, Asst. Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.
SCIENTIFIC PROJECTS-III	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Sezgin Sarıkaya, MD, Assoc. Prof. Mustafa Ferudun Çelikmen, MD, Asst. Prof. Pınar Tura, MD, Asst. Prof. Vildan Öztürk, MD, Asst. Prof. Rasim Yılmazer, MD, Asst. Prof. Serdar Özdemir, MD, Asst. Prof. Mustafa Yazıcıoğlu, MD. Cem Şimşek, MD.

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM
AIMS and LEARNING OBJECTIVES

INFECTIOUS DISEASES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on structures of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2. ***to convey*** knowledge on epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3. ***to convey*** knowledge on pathogenesis mechanisms of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
4. ***to convey*** necessary knowledge on prevention of infectious clinical conditions, and protection or improvement of health against these conditions,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing infectious clinical conditions, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on pharmacology of drugs used in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
8. ***to convey*** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
9. ***to convey*** biostatistical knowledge required in design of medical research,
10. ***to convey*** necessary knowledge on genetical basis of clinical conditions,
11. ***to equip with*** basic clinical skills, (intravenous injection on phantom model), required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***explain*** basic characteristics of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2.1. ***recall*** structures, and
2.2. ***explain*** mechanisms of pathogenesis of agents (bacteria, viruses, fungi, parasites, prions) that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3.0. ***classify*** infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, based on causative agents and systems,

4.0. ***explain*** mechanisms of change in structure and function at molecular, cellular, tissue, system, multi-system and organismal levels in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

5.0. ***explain*** mechanisms of host immune response to and consequences in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

6.0. ***explain*** epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

7.0. ***explain*** requirements for prevention of infectious clinical conditions, and protection or improvement of health against these conditions, in healthy or susceptible individual or community,

8.0. ***explain*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

9.0. at multi-system level or related to a body system,

- for healthy conditions in an individual or community with a request against infectious clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:

9.1. practice of history taking and physical examination

9.2. evaluation of emergency case (sepsis and septic shock-C1)

9.3. approach to healthy individual or patient (fever-C1)

9.4. laboratory tests/examinations (urine sample collection-C1, urine strip/dipstick test-C1, urine culture-C1)

9.5. imaging tests/examinations (nuclear medicine tests in infectious diseases-C1)

9.6. point of care testing (urine strip/dipstick test-C1)

9.7. making preliminary diagnosis or definitive diagnosis decision

9.8. making non-intervention or intervention decision

9.9. practicing non-intervention or intervention

9.10. referral/transport of healthy individual or patient

10.1.***list*** goals and principles of drug use,

10.2.***describe*** effects,

10.3.***explain*** mechanism of action (pharmacodynamics),

10.4.***list*** indications, contraindications, pharmacological features, pharmacokinetic characteristics, drug-drug inreactions and side effects,

10.5.***explain*** resistance mechanisms of drugs (principles of antimicrobial chemotherapy, antibacterial, antifungal, antiviral, antiprotozoal, antihelmintic drugs, antiseptics and disinfectants) used in infectious clinical conditions,

11.0. ***explain*** interactions of health conditions (healthy and clinical conditions) at individual, family and community levels in relation to infectious agents, and importance of infectious agents and infectious clinical conditions from the aspect of public health,

12.0.***define*** approaches (education, santitation, hygiene, disinfection/antisepsis/sterilization, screening, surveillance, vaccination, prophylaxis, isolation, design/renovation) to control risks in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health,

14.0. ***explain*** hereditary immune system disorders,

15.0.***explain*** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,

16.0. ***define*** biostatistical knowledge required in design of medical research (research design, planning medical research,
17.0. ***perform*** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.
18.0.***explain*** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,
19.0. ***define*** biostatistical knowledge required in design of medical research (research design, planning medical research,
20.0. ***perform*** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.

HEMATOPOIETIC SYSTEM

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of hematopoietic system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to hematopoietic system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
8. ***to convey*** knowledge on phytotherapeutic agents that have immune-modulatory effects,
9. ***to convey*** basic knowledge on phytotherapy
10. ***to convey*** knowledge on comparative biostatistical analysis of study groups,
11. ***to equip with*** basic and advanced clinical skills (arterial blood sample collection-C3) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1. ***recall*** anatomy, histology and physiology of hematopoietic system,
2. ***explain*** etiopathogenesis of clinical conditions (hematological syndromes, disorders and diseases, lenforeticular infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
3. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,

4. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. ***describe*** mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. at multi-system level and/or related to hematopoietic system,
   - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
   - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
   - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

6.1. practice of history taking and physical examination
6.2. evaluation of emergency case
6.3. approach to healthy individual or patient (anemia-C3, lymphadenopathy-C3)
6.4. laboratory tests/examinations (peripheral/venous blood collection for hematology tests-C3, hematology tests for anemia-C3)
6.5. imaging tests/examinations (nuclear medicine tests in hematology-C3)
6.6. point of care testing (hematology-peripheral blood smear examination-C3, hematology-complete blood count-)
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient

7. ***classify*** blood products and blood groups,
8. ***define*** principles of transfusion,
9. ***explain*** pharmacology of drugs (antianemic drugs, antineoplastic drugs, hematostatic drugs and blood products, immunomodulators) that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
10. ***explain*** mechanisms of bone marrow toxicity of drugs and other chemicals,
11. ***list*** principles of cancer chemotherapy,
12. ***explain*** chemotherapy in leukemia and lymphoma,
13. ***list*** phytotherapeutic agents with immunomodulatory effects,
14. ***list*** principles of comparative biostatistical analysis of study groups,
15. **perform** basic clinical skills, practiced on phantom models (arterial blood sample collection-C3), required at primary health care service.
16. ***explain*** basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine, regulations, standardization and quality control),

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM

COMMITTEE ASSESSMENT MATRIX

PHASE III **COURSE:** MD 302 INTRODUCTION TO CLINICAL SCIENCES **COURSE COMPONENT:** COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/ INSTRUCTOR**	**NUMBER OF QUESTIONS (MCQ)**			
			CE	**FE**	**IE**	**Total**
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	M. Sönmezoğlu	21	9	9	**39**
1.0.,3.0. (4.0.-12.0.)		A.Ç. Büke				
		İ.Ç. Acuner				
		B. A. Borsa				
	HEM	H. A. Özkan	6	3	3	**12**
	ONC	O.Ö.Eren	2	1	1	**4**
10.0.	PC	E. Genç	17	7	7	**31**
		Z. Gören				
4.0.,5.0.	PT	F. Özkan	9	5	5	**19**
4.0.,5.0.		I. D. Ekici				
4.0., 5.0.		A. S. Çöloğlu				
6.0.,7.0.,11.0.,12.0.	PH	R. E. Sezer	6	2	2	**10**
6.0.,7.0.,11.0.,12.0.		H. A.Taşyıkan				
15.0.	BED	H. Ertin/ R. Brömer	7	3	3	**13**
	IMM	G. Y. Demirel	5	2	2	**9**
16.0.	BS	Ç. Altunok	2	1	1	**4**
9.3. (6.0.-9.0.,11.0.,12.0.)	FM	G. İzbırak	1	0	0	**1**
4.0.,5.0.,8.0.	PP	M. Kaçar	3	1	1	**5**
14.0.	MG	A. Ç. Kuşkucu	4	2	2	**8**
9.2.	EM	S. Sarıkaya	1	0	0	**1**
8.0.,9.0., 9.1.	PED	S. Kemahlı H. Sarıçoban S. Yılmaz	4	2	2	**8**
	PHY	E. Yeşilada	2	1	1	**4**
TOTAL			90	39	39	**168**
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/ INSTRUCTOR**	**NUMBER OF QUESTIONS (EMQ)**			
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	M. Sönmezoğlu/ A.Ç. Büke/ İ.Ç. Acuner/ B.A.Borsa	2	-	-	**2**
10.0.	PC	E. Genç	1	-	-	**1**
	HEM	H.A. Özkan	1	-	-	**1**
4.0.,5.0.	PT	I. D. Ekici/ F. Özkan	1	-	-	**1**
TOTAL			**5**	-	-	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 pts; pts:points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

MCQ: Multiple Choice Question

EMQ: Extending Matching Question

CE: Committee Exam

CS: Committee Score

FE: Final Exam

ICE: Incomplete Exam

****39** out of 200 FE and ICE MCQs will be from Committee I (Each question is of worth **0.5** pts).

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM

WEEK I / 6 - 8 Sep 2017

	Monday 4-Sep-2017	Tuesday 5-Sep-2017	Wednesday 6-Sep-2017	Thursday 7-Sep-2017	Friday 8-Sep-2017
09.00- 09.50	**Religious Holiday**		**Introduction to Phase III**	**Independent Learning**	**Lecture** Scientific Projects - III: Project Writing G. Y. Demirel
10.00- 10.50			**Lecture** Pathophysiology of Infectious Diseases I M. Kaçar	**Microbiology Laboratory** (Antibacterial Susceptibility Testing) Microbiology Instructors	**Lecture** Introduction to Anemias in Childhood S. Kemahlı
11.00- 11.50			**Lecture** Pathophysiology of Infectious Diseases II M. Kaçar	GROUP A IL / GRPUP B IL / GROUP C IL / GROUP D IL	**Lecture** Antimicrobial Agents: Basic Concepts & Principles I İ.Ç. Acuner
12.00- 12.50			**Lecture** Laboratory Diagnosis of Infectious Diseases I İ.Ç. Acuner	GROUP A IL / GRPUP B / GROUP C IL / GROUP D IL	**Lecture** Antimicrobial Agents: Basic Concepts & Principles II İ.Ç. Acuner
12.50 - 14.00	**LUNCH BREAK**				
14.00- 14.50	**Religious Holiday**		**Lecture** Laboratory Diagnosis of Infectious Diseases II İ.Ç. Acuner	**Independent Learning**	**Lecture** Antimicrobial Agents: Mechanisms of Resistance I B.A. Borsa
15.00- 15.50			**Lecture** Laboratory Diagnosis of Infectious Diseases III İ.Ç. Acuner	**Independent Learning**	**Lecture** Antimicrobial Agents: Mechanisms of Resistance I B.A. Borsa
16.00- 16.50			**Lecture** Laboratory Diagnosis of Infectious Diseases IV B.A. Borsa	**Independent Learning**	**Lecture** Introduction to Hemolytic Anemias Thalassemias and Hemoglobinopathies (Sickle Cell Anemia and Others) S. Kemahlı
17.00-17.50			**Lecture** Laboratory Diagnosis of Infectious Diseases V B.A. Borsa	**Independent Learning**	**Lecture** Hemophilia and other Coagulopathies in Childhood S. Kemahlı

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK II / 11-15 Sep 2017

	Monday 11-Sep-2017	Tuesday 12-Sep-2017	Wednesday 13-Sep-2017	Thursday 14-Sep-2017	Friday 15-Sep-2017
09.00- 09.50	**Case Discussions** Pathology Tissue Response to Infections F. Özkan	**Independent Learning**	**Lecture** Parasitic Infections I A.Ç. Büke	**Microbiology Laboratory** (Antibacterial Susceptibility Testing) Microbiology Instructors	**Lecture** Introduction to Antimicrobial Chemotherapy E. Genç
10.00- 10.50	**Case Discussions** General Rewiev of Pathology of Infections Disease F. Özkan	**Lecture** ß Lactam Antibiotics I E. Genç	**Lecture** Fungal and Parasitic Skin and Soft Tissue Infections M. Sönmezoğlu	GROUP A IL | GRPUP B IL | GROUP C | GROUP D IL	**Lecture** Vancomycin & Other Cell Wall Synthesis Inhibitors E. Genç
11.00- 11.50	**Lecture** Semiology-I A.Ç. Büke	**Lecture** ß Lactam Antibiotics II E. Genç	**Lecture** Aminoglycosides E. Genç	GROUP C IL | GROUP D |	**Lecture** Macrolides Z. Gören
12.00- 12.50	**Lecture** Semiology-II A.Ç. Büke	**Independent Learning**	**Lecture** Sulfonamides, Chloramphenicol & Tetracyclines E. Genç	**Independent Learning**	**Lecture** Introduction to Scientific Projects G. Yanıkkaya Demirel
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Introduction to the Program of Family Medicine G. İzbırak	**Independent Learning**	**Lecture** Introduction to the Course I Ethics Lecturer	**Lecture** Planning Medical Studies I Ç. Altunok	**Microbiology Laboratory** (Laboratory Tests-I) Microbiology Instructors
15.00- 15.50	**Lecture** Pathology of Mycobacterial Infections F. Özkan	**Independent Learning**	**Lecture** Introduction to the Course II Ethics Lecturer	**Lecture** Planning Medical Studies II Ç. Altunok	GROUP A | GROUP B IL | GROUP C IL | GROUP D IL
16.00- 16.50	**Lecture** Case Discussion on Immunity to Infection G. Yanıkkaya Demirel	**Independent Learning**	**Independent Learning**	**Lecture** Research Design Ç. Altunok	GROUP A IL | GROUP B | GROUP C IL | GROUP D IL
17.00-17.50	**Lecture** Case Discussion on Immunity to Infection G. Yanıkkaya Demirel	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK III / 18-22 Sep 2017

	Monday 18-Sep-2017	Tuesday 19-Sep-2016	Wednesday 20-Sep-2017	Thursday 21-Sep-2017	Friday 22-Sep-2017
09.00- 09.50	**Lecture** Tuberculosis & Other Mycobacterial Infections I A.Ç. Büke	**Lecture** Hospital Infection M. Sönmezoğlu	**Lecture** Parasitic Infections II A.Ç. Büke	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Lecture** Zoonotic Diseases I M. Sönmezoğlu	**Lecture** Febril Neutropenia M. Sönmezoğlu	**Lecture** Vaccines A.Ç. Büke	**Independent Learning**	**Independent Learning**
11.00- 11.50	**Lecture** Zoonotic Diseases II M. Sönmezoğlu	**Lecture** Tuberculosis & Other Mycobacterial Infections II A.Ç. Büke	**Lecture** Introduction to Clinical Genetics A. Ç. Kuşkucu	**Independent Learning**	**Independent Learning**
12.00- 12.50	**Lecture** Antimycobacterial Drugs E. Genç	**Lecture** Anthelminthic Drugs **E. Genç**	**Lecture** Inherited Immune System Disorders A. Ç. Kuşkucu	**Independent Learning**	**Independent Learning**
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Physician-Patient Relationship Ethics Lecturer	**Lecture** Occupational Health Hazards I A.Ç. Büke	**Lecture** Bacterial and Viral Skin & Soft Tissue Infections M. Sönmezoğlu	**Independent Learning**	**Independent Learning**
15.00- 15.50	**Lecture** Confidentiality and Truthfulness Ethics Lecturer	**Lecture** Occupational Health Hazards II A.Ç. Büke	**Lecture** Infections in Immuncompromised Host M. Sönmezoğlu	**Independent Learning**	**Independent Learning**
16.00- 16.50	**Independent Learning**	**Independent Learning**	**Lecture** Public Health and Communicable Diseases-I R.E. Sezer	**Independent Learning**	**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Lecture** Public Health and Communicable Diseases-**II** R.E. Sezer	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK IV / 25-29 Sep 2017

	Monday 25-Sep-2017	Tuesday 26-Sep-2017	Wednesday 27-Sep-2017	Thursday 28-Sep-2017	Friday 29-Sep-2017
09.00- 09.50	**Lecture** Pathophysiology of Hematopoietic System Disorders I M. Kaçar	**Independent Learning**	**Lecture** Antimalarial Drugs Z. Gören	**Independent Learning**	**Lecture** Pharmacological Basis of Cancer Therapy I Z. Gören
10.00- 10.50	**Lecture** Pathophysiology of Hematopoietic System Disorders II M. Kaçar	**ICP-CSL** (Suturing technique) M. F. Çelikmen	**Lecture** Quinolones Z. Gören	**ICP-CSL** (Suturing technique) V. Öztürk	**Lecture** Pharmacological Basis of Cancer Therapy II Z. Gören
11.00- 11.50	**Lecture** Antiviral Drugs Z. Gören	**Group A ICP** / **Group B Small Group Study** Scientific Project / **Group C IL** / **Group D IL**	**Lecture** Prevention and Control of Communicable Diseases I R. E. Sezer	**Group A Small Group Study** Scientific Project / **Group B ICP** / **Group C IL** / **Group D IL**	**Lecture** Pathology of Viral Infections I I. D. Ekici
12.00- 12.50	**Lecture** Emergency Evaluation of Sepsis and Septic Shock M. F. Çelikmen		**Lecture** Prevention and Control of Communicable Diseases II R. E. Sezer		**Lecture** Pathology of Viral Infections II I. D. Ekici
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Approach to the Pediatric Patient with Fever P. Saf	**Lecture** Beneficence and Non-Maleficence Ethics Lecturer	**Lecture** Immune Acquired Hemolytic Anemias / Non Immune Acquired Hemolytic Anemias A . Özkan	**Lecture** Aplastic and Hypoplastic Anemias A. Özkan	**Lecture** Antianemic Drugs E. Genç
15.00- 15.50	**Independent Learning**	**Lecture** Transplantation Ethics Lecturer	**Lecture** Molecular Basis of Hemoglobinopathies A. Ç. Kuşkucu	**Lecture** Nutritional Anemias A. Özkan	**Lecture** Antiprotozoal Drugs Z. Gören
16.00- 16.50	**Independent Learning**	**Lecture** Principles of Autonomy and Informed Consent Ethics Lecturer	**Independent Learning**	**Lecture** Antifungal Drugs Z. Gören	**Independent Learning**
17.00-17.50	**Independent Learning**	**Lecture** Justice in Medicine Ethics Lecturer	**Independent Learning**	**Lecture** Antiseptics and Disinfectants Z. Gören	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK V / 2-6 Oct 2017

<table>
<tr><th></th><th>Monday
2-Oct-2017</th><th>Tuesday
3-Oct-2017</th><th>Wednesday
4-Oct-2017</th><th>Thursday
5-Oct-2017</th><th>Friday
6-Oct-2017</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Pathology of Bone Marrow-1
I D. Ekici</td><td>ICP-CSL
(Suturing technique)
M. Yazıcıoğlu / C. Şimşek</td><td>Lecture
Hodgkin's Lymphoma
I D. Ekici</td><td colspan="4">Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Pathology of Bone Marrow-2
I D. Ekici</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B IL</td><td rowspan="2">Group C
Small Group Study
Scientific Project</td><td rowspan="2">Group D ICP</td><td>Lecture
Pathology of Myeloproliferative Diseases-I
I D. Ekici</td><td colspan="4">ICP
(Ear-Nose-Throat Examination)
R. Yılmazer/ S. Özdemir</td><td>Independent Learning</td></tr>
<tr><td>11.00- 11.50</td><td colspan="2">Microbiology Laboratory
(Laboratory Tests-I)
Microbiology Instructors</td><td rowspan="2">Lecture
Pathology of Myeloproliferative Diseases II
I D. Ekici</td><td rowspan="2">Group A ICP</td><td rowspan="2">Group B
Small Group Study
Scientific Project</td><td rowspan="2">Group C IL</td><td rowspan="2">Group D IL</td><td>Independent Learning</td></tr>
<tr><td>12.00- 12.50</td><td>Group A IL</td><td>Group B IL</td><td>Group C</td><td>Group D IL</td><td colspan="2">Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>12.50- 14.00</td><td colspan="7">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td colspan="2">ICP-CSL
(Suturing technique)
P. Türe</td><td rowspan="3">Microbiology Laboratory Make-up
(Antibacterial & Susceptibility Testing)
Microbiology Instructors</td><td>Independent Learning</td><td colspan="3">ICP
(Ear-Nose-Throat Examination)
R. Yılmazer/ S. Özdemir</td><td>Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B IL</td><td rowspan="2">Group C ICP</td><td rowspan="2">Independent Learning</td><td>Independent Learning</td><td rowspan="2">Group A
Small Group Study
Scientific Project</td><td rowspan="2">Group B ICP</td><td rowspan="2">Group C IL</td><td rowspan="2">Group D IL</td><td>Independent Learning</td></tr>
<tr><td>16.00- 16.50</td><td>Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>17.00-17.50</td><td colspan="2">Independent Learning</td><td>Independent Learning</td><td>Independent Learning</td><td colspan="3">Independent Learning</td><td>Independent Learning</td></tr>
</table>

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK VI / 9-13 Oct 2017

	Monday 9-Oct-2017	Tuesday 10-Oct-2017	Wednesday 11-Oct-2017	Thursday 12-Oct-2017	Friday 13-Oct-2017
09.00- 09.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Lymphoreactive Disease I. D. Ekici
10.00- 10.50	**Lecture** Quantitative and Qualitative Platelet Disorders A. Özkan	**Lecture** Non/Hodgkin's Lymphoma I I D. Ekici	**Lecture** Introduction to Clinical Oncology I O .Ö. Eren	**ICP** (Ear-Nose-Throat Examination) R. Yılmazer/ S. Özdemir	**Lecture** Pathology of Spleen I. D. Ekici
11.00- 11.50	**Lecture** Hypercoagulability A. Özkan	**Lecture** Non/Hodgkin's Lymphoma II I D. Ekici	**Lecture** Introduction to Clinical Oncology II O .Ö. Eren	**Group A** **IL** **Group B** **IL** **Group C** **ICP** **Group D** **Small Group Study** Scientific Project	**Lecture** Genetics of Oncology I A. Ç. Kuşkucu
12.00- 12.50	**Lecture** Plasma Cell Dyscrasias A. Özkan	**Lecture** Congenital Immunodeficiency Disease H. Sarıçoban	**Lecture** Treatment Approaches of Cancer O .Ö. Eren		**Lecture** Genetics of Oncology II A. Ç. Kuşkucu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Approach to the Patient with Anemia and Laboratory Tests in Diagnosis with Anemia A. Özkan	**Independent Learning**	**Lecture** Phytotherapy I E. Yeşilada	**Lecture** Lymphoma A. Özkan	**Lecture** Transplantation Immunology G. Yanıkkaya Demirel
15.00- 15.50	**Lecture** Immunodeficiencies G. Yanıkkaya Demirel	**Independent Learning**	**Lecture** Phytotherapy II E. Yeşilada	**Lecture** Acute Leukemias A. Özkan	**Lecture** Transplantation Immunology G. Yanıkkaya Demirel
16.00- 16.50	**Lecture** Immunodeficiencies G. Yanıkkaya Demirel	**Independent Learning**	**Lecture** Phytotherapy III E. Yeşilada	**Independent Learning**	**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK VII / 16-20 Oct 2017

<table>
<tr><th></th><th colspan="4">Monday
16-Oct-2017</th><th>Tuesday
17-Oct-2017</th><th>Wednesday
18-Oct-2017</th><th>Thursday
19-Oct-2017</th><th>Friday
20-Oct-2017</th></tr>
<tr><td>09.00- 09.50</td><td colspan="4">Independent Learning</td><td>Independent Learning</td><td>Lecture
Lenforeticular Infections I
A.Ç. Büke</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td colspan="4">Lecture
Immunomodulators
Z. Gören</td><td>Lecture
Blood Components and Transfusion Indications
M. Sönmezoğlu</td><td>Lecture
Lenforeticular Infections II
A.Ç. Büke</td></tr>
<tr><td>11.00- 11.50</td><td colspan="4">Lecture
Hematostatic Drugs and Hematostatic Blood Products I
E. Genç</td><td>Lecture
Blood Groups
M. Sönmezoğlu</td><td>Lecture
Myeloproliferative Diseases
A. Özkan</td></tr>
<tr><td>12.00- 12.50</td><td colspan="4">Lecture
Hematostatic Drugs and Hematostatic Blood Products II
E. Genç</td><td>Lecture
Approach to the Patient with LAP
H. Akan</td><td>Lecture
Chronic Leukemia
A. Özkan</td></tr>
<tr><td>12.50-14.00</td><td colspan="8">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td colspan="4">Independent Learning</td><td>Lecture
Epidemiology of Communicable Diseases I
H.A.Taşyıkan</td><td>Lecture
Investigation of a Disease Epidemic I
H.A.Taşyıkan</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td colspan="4">ICP
(Ear-Nose-Throat Examination)
R. Yılmazer/ S. Özdemir</td><td>Lecture
Epidemiology of Communicable Diseases II
H.A.Taşyıkan</td><td>Lecture
Investigation of a Disease Epidemic II
H.A.Taşyıkan</td></tr>
<tr><td>16.00- 16.50</td><td rowspan="2">Group A
IL</td><td rowspan="2">Group B
IL</td><td rowspan="2">Group C
Small Group Study
Scientific Project</td><td rowspan="2">Group D
ICP</td><td>Lecture
Bioethics
Ethics Lecturer</td><td>Multidisciplinary Case Discussion Panel</td></tr>
<tr><td>17.00-17.50</td><td>Lecture
Responsible Biomedical Research
Ethics Lecturer</td><td>Multidisciplinary Case Discussion Panel</td></tr>
</table>

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM

WEEK VIII / 23-27 Oct 2017

	Monday 23-Oct-2017	Tuesday 24-Oct-2017	Wednesday 25-Oct-2017	Thursday 26-Oct-2017	Friday 27-Oct-2017
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Program Evaluation Session Committee I Coordination Committee Members
15.00- 15.50					Independent Learning
16.00- 16.50					
17.00-17.50					

COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS

DISTRIBUTION of LECTURE HOURS
October 30, 2017 – December 15, 2017
COMMITTEE DURATION: 7 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	PHARMACOLOGY	PC	25				**25**
	PATHOLOGY	PT	24	1x3=3 (2 Groups)			**27**
	CHEST MEDICINE	CHM	18				**18**
	CARDIOLOGY	CRD	14				**14**
	PUBLIC HEALTH	PH	8				**8**
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	9				**9**
	PATHOPHYSIOLOGY	PP	6				**6**
	INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	IDCM	5				**5**
	ENT DISEASES	ENT	4				**4**
	THORACIC SURGERY	TS	3				**3**
	FAMILY MEDICINE	FM	4				**4**
	MEDICAL GENETICS	MG	2				**2**
	BIOISTATISTICS	BS	4				**4**
	PEDIATRICS	PED	3				**3**
	RADIOLOGY	RAD	1				**1**
	EMERGENCY MEDICINE	EM	1				**1**
	IMMUNOLOGY	IMM	2				**2**
	SCIENTIFIC PROJECTS-III	SP	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			2x3=6 (4 Groups)		**6**
TOTAL			**134**	**3**	**6**	**2**	**145**

Coordination Committee

HEAD	Işın D. Ekici, MD, Prof.
SECRETARY	Mustafa Aytek Şimşek, MD, Asst. Prof.
MEMBER	Hülya Sarıçoban, MD, Assoc. Prof.
MEMBER	Banu Musaffa Salepçi, Assoc. Prof.
MEMBER	Hale Arık Taşyıkan, MD, Asst. Prof.

COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
PHARMACOLOGY	Ece Genç, PhD, Prof. Feyza Arıcıoğlu, PhD, Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD, Prof.
CHEST MEDICINE	Banu Musaffa Salepçi, MD, Assoc. Prof.
CARDIOLOGY	Muzaffer Değertekin, MD, Prof. Olcay Özveren, MD, Asst. Prof. AyçaTürer Cabbar, MD Mustafa Aytek Şimşek, MD
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof. Hale Arık Taşyıkan, MD, Asst. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Hakan Ertin, MD, Assoc. Prof. Rainer Brömer, PhD, Assoc. Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof. A. Çağrı Büke, MD, Prof
EAR- NOSE -THROAT (ENT)	Yavuz Selim Pata, MD, Prof. Müzeyyen Doğan, MD, Assoc. Prof.
THORACIC SURGERY	Sina Ercan, MD, Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Assoc.Prof.
PEDIATRICS	Hülya Sarıçoban, MD, Assoc. Prof. Mustafa Berber, MD, Asst. Prof. Fatma Tuba Coşkun, MD
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
RADIOLOGY	Emrah Karatay, MD.
RADIATION ONCOLOGY	Halim Aydın, MD, Assoc. Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Asst.Prof.
BIOSTATISTICS	Çiğdem Altunok, PhD, Asst. Prof
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Güldal İzbırak, MD, Assoc. Prof. Ferdi Menda MD, Assoc.Prof. Olcay Özveren, MD, Asst. Prof. Serdar Özdemir, MD, Asst. Prof. Sevgi Bilgen, MD, Asst. Prof Ayça Türer Cabbar, MD Mustafa Aytek Şimşek, MD

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of cardiovascular and respiratory systems,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
6. ***to convey*** necessary knowledge together **with performance measures** on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to cardiovascular and respiratory systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the level of primary health care service,**
7. ***to convey*** knowledge on principles of prescription,
8. ***to convey*** necessary knowledge on pharmacology of drugs effective on cardiovascular system,
9. ***to convey*** necessary knowledge on radiation physics and biology and its use in oncology,
10. ***to convey*** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
11. ***to convey*** knowledge on principles of biostatistical analysis,
12. **to equip with basic and advanced clinical skills** (advanced cardiac life support-C2, approach to patient with cardiovascular clinical condition-C2) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.***recall*** anatomy, histology and physiology of cardiovascular and respiratory systems,

2.***explain*** etiopathogenesis of clinical conditions (*upper respiratory tract problems -nasal obstruction, etc.-, infectious clinical conditions with upper and lower respiratory tract and lung involvement -pneumonia, tuberculosis, etc.-, circulatory lung disorders -pulmonary embolism, etc.-, obstructive/restrictive lung diseases, respiratory insuffiency, tobacco use, lung tumors,other lung diseases; diseases of coronary circulation and coronary arteries, diseases of cardiac valves, myocardial and pericardial diseases, blood stream infections and sepsis, cardiac problems in adults and children, mediastinal diseases, nasopharyngeal and oropharyngeal diseases, nasal and paranasal sinus diseases, diseases of middle ear and eustachian tube, laryngeal diseases, voice disorders*) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

3.***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

4.***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,

5.***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

6.at multi-system level and/or related to cardiovascular and respiratory systems,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes, health care processes, clinical decision making process, clinical decisions and clinical practices

- which are required for management at primary health care service level:

6.1. practice of history taking and physical examination (cardiovascular-C2, pulmonary-C2)

6.2. evaluation of emergency case (dyspnea-C2)

6.3. approach to healthy individual or patient (cardiovascular disease-C2, chest pain-C2, cough and hemoptysis-C2, dyspnea-C2)

6.4. laboratory tests/examinations (cardiac markers-, coagulation tests-, blood gases-, pulmonary function tests-C2)

6.5. imaging tests/examinations (radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac PET-C2, ventilation/perfusion scintigraphyi-C2, PET in lung cancer-C2)

6.6. point of care testing (urine strip/dipstick test-C1)

6.7. making preliminary diagnosis or definitive diagnosis decision

6.8. making non-intervention or intervention decision

6.9. practicing non-intervention or intervention

6.10. referral/transport of healthy individual or patient

7.***define*** radiation physics, biology and its use in oncology,

8.***explain*** implementation of hypertension treatment guidelines,

9.***explain*** pharmacology of drugs effective on cardiovascular system (autonomic system pharmacology, renin-angiotensin system pharmacology, calcium channel blockers, pharmacological approach to ischemic and congestive cardiovascular conditions, drugs effecting body fluids and volume, anti-hypertension drugs, hypolipidemic drugs, antiarrhythmic drugs, antiplatelet, antithrombotic and thrombolytic drugs, drugs used in the treatment of asthma and chronic obstructive pulmonary disease, antitussive, expectorant and surfactant drugs),

10.***explain*** ethical problems (rejection of treatment, organ transplantation, paternalism, reproductive and negative rights),

11.***explain*** principles of biostatistical analysis,

12.***perform*** basic clinical skills, practiced on phantom models (advanced cardiac life support-C2), and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with cardiovascular clinical condition-C2), required at primary health care service.96

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
COMMITTEE ASSESSMENT MATRIX

PHASE III
COURSE: MD 302 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT: COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS

QUESTION DISTRIBUTION TABLE

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
8.0.,9.0.	PC	E. Genç	16	7	7	30
9.0.		F. Arıcıoğlu				
1.0.,2.0.	PT	F. Özkan	16	7	7	30
1.0.,2.0.		I. D. Ekici				
1.0.,2.0.,5.0.,6.0.,6.1.,6.4.,6.5.,6.6.	CHM	B. Salepçi	12	6	6	24
1.0.,2.0.,5.0.,6.0.6.4.	CRD	M. Değertekin	9	4	4	17
1.0.,2.0., 5.0., 6.0.6.1.,6.3.		O. Özveren				
1.0.,2.0.,5.0.,6.0.6.4.		A.Cabbar				
		M.A. Şimşek				
3.0.,4.0.	PH	R.E. Sezer	5	2	2	9
3.0.,4.0.		H.A.Taşyıkan				
10.0.	BED	H. Ertin / R. Brömer	6	3	3	12
2.0.,5.0.	PP	M. Kaçar	4	2	2	8
2.0.,5.0.,6.0.	IDCM	M. Sönmezoğlu	4	2	2	7
		A. Ç. Büke				
1.0.,2.0.,5.0.,6.0.	ENT	Y. Selim Pata	3	1	1	5
		M. Doğan				
1.0.,2.0.,5.0.,6.0.	FM	G. İzbırak	3	1	1	5
1.0.,2.0.,5.0.,6.0.		Ö. Tanrıöver				
1.0.,2.0.,5.0.,6.0.	BS	Ç. Altunok	3	1	1	5
2.0.,5.0.	PED	S. Sarıçoban	2	1	1	4
6.3.		M. Berber				
6.3.	TS	S. Ercan	2	1	1	4
6.2.	MG	A. Ç. Kuşkucu	1	1	1	3
	IMM	G. Y. Demirel	1	1	1	4
	RONC	H. Aydın	1	1	1	3
6.5.	RAD	E. Karatay	1	0	0	1
11.0.	EM	F. Çelikmen	1	0	0	1
TOTAL			**90**	**41**	**41**	**172**

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.,2.0.,5.0.,6.0.,6.1.,6.4.,6.5.,6.6.	CHM	B. Salepçi	1	-	-	1
1.0.,2.0.,5.0.,6.0.,6.3.,6.4.	PT	ID. Ekici	2	-	-	2
8.0.,9.0.	PC	E. Genç	2	-	-	2
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 pts; pts:points**
*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.
MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
****41** out of 200 FE and ICE MCQs will be from Committee II (Each question is of worth **0.5** pts).

COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK I / 30 Oct – 3 Nov 2017

	Monday 30-Oct-2017	Tuesday 31-Oct-2017	Wednesday 1-Nov-2017	Thursday 2-Nov-2017	Friday 3-Nov-2017
09.00- 09.50	**Independent Learning**	**Lecture** Congestive Heart Failure F. Özkan	**Lecture** Examination of the Heart M. Değertekin	**ICP-CSL** (Advanced Cardiac Life Support) F. Menda/ S. Bilgen	**Lecture** Electrocardiography I M. Değertekin E. Aslanger
10.00- 10.50	**Lecture** Ethics of Publication Ethics Lecturer	**Lecture** Congestive Heart Failure & Pericardium F. Özkan	Coronary Artery Disease I M. Değertekin	**Group A ICP** / **Group B IL** / **Group C IL** / **Group D IL**	**Lecture** Electrocardiography II M. Değertekin E. Aslanger
11.00- 11.50	**Lecture** Ethical Issues at the Beginning of Life Ethics Lecturer	**Lecture** Preparing to Analyse Data Ç. Altunok	**Lecture** Coronary Artery Disease II M. Değertekin		**Independent Learning**
12.00- 12.50	**Lecture** Ethical Issues in Paediatrics Ethics Lecturer	**Lecture** Introduction to Autonomic System Pharmacology E. Genç	**Lecture** Ischemic Heart Disease I F. Özkan	**Independent Learning**	**Independent Learning**
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pathophysiology of Cardiovascular System Disorders I M. Kaçar	**Lecture** Pharmacology of ReninAngiotensin System F. Arıcıoğlu	**Lecture** Myocardium F. Özkan	**Lecture** Approach to the Patient with Cardiovascular System Diseases M. A. Şimşek	**Lecture** General Signs and Principal Symptoms in Cardiovascular System Diseases O. Özveren A. Türer Cabbar
15.00- 15.50	**Lecture** Pathophysiology of Cardiovascular System Disorders II M. Kaçar	**Independent Learning**	**Lecture** Acetylcholine and Directly Acting Parasympathomimetic Drugs E. Genç	**Lecture** Cardiac Arrhythmias I M. A. Şimşek	**Lecture** Congestive Heart Failure I O.Özveren A. Türer Cabbar
16.00- 16.50	**Lecture** Pathophysiology of Cardiovascular System Disorders III M. Kaçar	**Independent Learning**	**Lecture** Acetylcholinesterase Inhibitors E. Genç	**Lecture** Cardiac Arrhythmias II M. A. Şimşek	**Lecture** Congestive Heart Failure II O. Özveren A. Türer Cabbar
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK II / 6 - 10 Nov 2017

	Monday 6-Nov-2017	Tuesday 7-Nov-2017	Wednesday 8-Nov-2017	Thursday 9-Nov-2017	Friday 10-Nov-2017
09.00- 09.50	**Lecture** Pathology of Endocardium & Heart Valves I I.D. Ekici	**Lecture** Atherosclerosis & Hypertension I I.D. Ekici	**Lecture** Infective Endocarditis and Acute Rheumatic Fever O. Özveren A. Türer Cabbar	**ICP-CSL** (Advanced Cardiac Life Support) F. Menda/ S. Bilgen	**Commomeration of Ataturk (Rectorate Building, Inan Kıraç Conference Hall)**
10.00- 10.50	**Lecture** Pathology of Endocardium & Heart Valves II I.D. Ekici	**Lecture** Atherosclerosis & Hypertension II I.D. Ekici	**Lecture** Aortic Valvular Heart Diseases O. Özveren A. Türer Cabbar	**Group A** **Small Group Study** Scientific Project **Group B** **ICP** **Group C IL** **Group D IL**	
11.00- 11.50	**Lecture** Adrenergic Receptor Blockers E. Genç	**Lecture** Bloodstream Invasion & Sepsis I M. Sönmezoğlu	**Lecture** Mitral Valvular Heart Diseases O. Özveren A. Türer Cabbar		
12.00- 12.50	**Lecture** Adrenergic Neuron Blockers E. Genç	**Lecture** Ischemic Heart Disease II F. Özkan	**Lecture** Pharmacology Case Studies E. Genç	**Independent Learning**	
12.50 - 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Epidemiology and Prevention of Cardiovascular Diseases I H. A.Taşyıkan	**Lecture** Diuretic Agents I F. Arıcıoğlu	**Lecture** Rheumatic Heart Disease I. D. Ekici	**Lecture** Drugs Used in the Treatment of Angina Pectoris F. Arıcıoğlu	**Independent Learning**
15.00- 15.50	**Lecture** Epidemiology and Prevention of Cardiovascular Diseases II H. A.Taşyıkan	**Lecture** Diuretic Agents II F. Arıcıoğlu	**Lecture** CVS Tumors I. D. Ekici	**Lecture** Drugs Used in Cardiac Arrythmias I F. Arıcıoğlu	**Independent Learning**
16.00- 16.50	**Lecture** Public Health and Chronic Non-Communicable Diseases H. A. Taşyıkan	**Lecture** Parasympatholitic Drugs E. Genç	**Lecture** Approach to Patient with Chest Pain in Primary Care I G. İzbırak	**Lecture** Drugs Used in Cardiac Arrythmias II F. Arıcıoğlu	**Independent Learning**
17.00-17.50	**Independent Learning**	**Lecture** Sympathomimetic Drugs: Catecholamines & Noncatecholamines E. Genç	**Lecture** Approach to Patient with Chest Pain in Primary Care II G. İzbırak	**Independent Learning**	**Independent Learning**

COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK III / 13-17 Nov 2017

	Monday 13-Nov-2017	Tuesday 14-Nov-2017	Wednesday 15-Nov-2017	Thursday 16-Nov-2017	Friday 17-Nov-2017
09.00- 09.50	**Independent Learning**	**Lecture** Drugs Used in the Treatment of Dyslipidemias I F. Arıcıoğlu	**Independent Learning**	**ICP-CSL** (Advanced Cardiac Life Support) F. Menda/ S. Bilgen	**Independent Learning**
10.00- 10.50	**Lecture** Hypertension Treatment Guidelines F. Arıcıoğlu	**Lecture** Drugs Used in the Treatment of Dyslipidemias II F. Arıcıoğlu	**Independent Learning**	**Group A IL** / **Group B IL** / **Group C ICP** / **Group D Small Group Study** Scientific Project	**Lecture** Respiratory Muscles and Surgical Anatomy of Thorax S. Ercan
11.00- 11.50	**Lecture** Anti-hypertensive Drugs I F. Arıcıoğlu	**Lecture** Congenital Heart Disease in Pediatrics M. Berber / T. Giray	**Independent Learning**		**Lecture** Surgical Disorders of Mediastinum and the Diaphragm S. Ercan
12.00- 12.50	**Lecture** Anti-hypertensive Drugs II F. Arıcıoğlu	**Lecture** Inherited Cardiovascular Disorders A.Ç. Kuşkucu	**Independent Learning**	**Independent Learning**	**Lecture** Surgical Treatment of Pulmonary Diseases S. Ercan
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Anticoagulant, Antiplatelet & Thrombolytic drugs F. Arıcıoğlu	**Lecture** Pathophysiology of Respiratory System Disorders I M. Kaçar	**Lecture** History and Symptoms in Pulmonary Diseases B. Salepçi	**Independent Learning**	**Lecture** Ethics in Intensive Care Ethics Lecturer
15.00- 15.50	**Lecture** Ethical Issues at the End of Life Ethics Lecturer	**Lecture** Pathophysiology of Respiratory System Disorders II M. Kaçar	**Lecture** Physical Examination and Signs in Pulmonary Diseases B. Salepçi	**Independent Learning**	**Lecture** Ethics in Psychiatry Ethics Lecturer
16.00- 16.50	**Lecture** Palliative Care Ethics Ethics Lecturer	**Lecture** Pathophysiology of Respiratory System Disorders III M. Kaçar	**Lecture** Respiratory Failure B. Salepçi	**Independent Learning**	**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK IV/ 20-24 Nov 2017

	Monday 20-Nov-2017	Tuesday 21-Nov-2017	Wednesday 22-Nov-2017	Thursday 23-Nov-2017	Friday 24-Nov-2017
09.00- 09.50	**Lecture** Diagnostic Methods in Pulmonary Medicine B. Salepçi	**Lecture** Pneumonia B. Salepçi	**Independent Learning**	**ICP-CSL** (Advanced Cardiac Life Support) F. Menda/ S. Bilgen	**Lecture** Chronic Obstructive Pulmonary Diseases F. Özkan
10.00- 10.50	**Lecture** Clinical Application of Pulmonary Function Tests B. Salepçi	**Lecture** Interstitial Lung Diseases B. Salepçi	**Lecture** Pleural Diseases B. Salepçi	**Group A IL** / **Group B IL** / **Group C Small Group Study** Scientific Project / **Group D ICP**	**Lecture** Asthma Bronchiale F. Özkan
11.00- 11.50	**Lecture** Pulmonary Tuberculosis B. Salepçi	**Lecture** Bronchiectasis B. Salepçi	**Lecture** Sleep Apnea Syndrome B. Salepçi		**Lecture** Congenital Lung Anomalies & Atalectasis F. Özkan
12.00- 12.50	**Lecture** X-Ray Examination of the Lungs E. Karatay	**Lecture** Treatment of Cough & Drugs Used in the Treatment of Common Cold F. Arıcıoğlu	**Lecture** Emergency Evaluation of Dyspnea M.F. Çelikmen	**Lecture** Pathology of Upper Respiratory Tract F. Özkan	**Lecture** Inherited Respiratory System Disorders A. Kuşkucu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Introduction to Radiation Oncology H. Aydın	**Lecture** Medical Ethical Decision-Making Ethics Lecturer	**Lecture** Laryngeal and Voice Diseases M. Doğan	**Lecture** Lung Cancer B. Salepçi	**Independent Learning**
15.00- 15.50	**Lecture** Basics of Radiation Biology and Radiation Physics H. Aydın	**Lecture** Ethics and the Law Ethics Lecturer	**Lecture** Diseases of the Middle Ear and Eustachian Tube M. Doğan	**Lecture** Tracheobronchitis B. Salepçi	
16.00- 16.50	**Lecture** Diseases of the Nose and Paranasal Sinuses Y. S. Pata	**Lecture** Drugs Used in Congestive Heart Disease I F. Arıcıoğlu	**Lecture** Principals of Statistical Analysis I Ç. Altunok	**Lecture** Pulmonary Infections I F. Özkan	
17.00-17.50	**Lecture** Nasopharyngeal and Oropharyngeal Diseases Y. S. Pata	**Lecture** Drugs Used in Congestive Heart Disease II F. Arıcıoğlu	**Lecture** Principals of Statistical Analysis II Ç. Altunok	**Lecture** Pulmonary Infections II F. Özkan	

COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK V / 27 Nov – 1 Dec 2017

<table>
<tr><th></th><th>Monday
27-Nov-2017</th><th>Tuesday
28-Nov-2017</th><th>Wednesday
29-Nov-2017</th><th>Thursday
30-Nov-2017</th><th>Friday
1-Dec-2017</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Pulmonary Hypertension
B. Salepçi</td><td>Lecture
Tobacco Control and Chronic Non-Communicable Diseases I
R.E. Sezer</td><td>Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Special Pulmonary Problems
B. Salepçi</td><td>Lecture
Tobacco Control and Chronic Non-Communicable Diseases II
R.E. Sezer</td><td>Lecture
Tumors of the Respiratory System I
I.D. Ekici</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Approach to the Pediatric Patient with Pneumonia
H. Sarıçoban</td><td>Lecture
Tobacco Control and Chronic Non-Communicable Diseases III
R.E. Sezer</td><td>Lecture
Tumors of the Respiratory System II
I.D. Ekici</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Chest Medicine Case Reports
H. Sarıçoban</td><td>Independent Learning</td><td>Lecture
Pathology of Pleural and Mediastinal Diseases
I.D. Ekici</td><td>Lecture
Drugs Used in the Treatment of Asthma & Chronic Obstructive Lung Disease
F. Arıcıoğlu</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td colspan="2">ICP-CSL
(History taking & examination of cardiovascular system)
O. Özveren / M. A. Şimşek /
S. Özdemir/ G. İzbırak</td><td colspan="2">ICP-CSL
(History taking & examination of cardiovascular system)
O. Özveren / M. A. Şimşek /
S. Özdemir/ G. İzbırak</td><td rowspan="3">Pathology Laboratory
(Cardiovascular and Respiratory Systems)
F. Özkan/ I.D. Ekici</td><td rowspan="2">Group A</td><td>Group B IL</td><td>Lecture
Pulmonary Embolism
B. Salepçi</td><td rowspan="4">Independent Learning</td></tr>
<tr><td rowspan="2">15.00- 15.50</td><td rowspan="3">Group C
ICP</td><td rowspan="3">Group D
Small Group Study
Scientic Project</td><td rowspan="3">Group A IL</td><td rowspan="3">Group B IL</td><td rowspan="3">Group C
Small Group Study
Scientific Project</td><td rowspan="3">Group D
ICP</td><td rowspan="3">Group A IL</td><td rowspan="3">Group B IL</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B</td><td rowspan="2">Lecture
Bronchial Hyperreactivity and Asthma
B. Salepçi</td></tr>
<tr><td>16.00- 16.50</td><td>Lecture
Chronic Obstructive Pulmonary Disease
B. Salepçi</td></tr>
<tr><td>17.00-17.50</td><td colspan="2">Independent Learning</td><td colspan="2">Independent Learning</td><td colspan="3">Independent Learning</td><td>Independent Learning</td></tr>
</table>

COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK VI / 4-8 Dec 2017

	Monday 4-Dec-2017	Tuesday 5-Dec-2017	Wednesday 6-Dec-2017	Thursday 7-Dec-2017	Friday 8-Dec-2017
09.00- 09.50	**Lecture** Approach to the Patient with Cough and Heameoptysis in Primary Care Ö. Tanrıöver	**Lecture** Upper and Lower Respiratory System Infections I A.Ç. Büke	**ICP-CSL** (History taking & examination of cardiovascular system) O. Özveren / A. Türer Cabbar / S. Özdemir/ G. İzbırak	**ICP-CSL** (History taking & examination of cardiovascular system) O. Özveren / M. A. Şimşek / S. Özdemir/ G. İzbırak	**Independent Learning**
10.00- 10.50	**Lecture** Approach to the Patient with Dyspnea in Primary Care Ö. Tanrıöver	**Lecture** Upper and Lower Respiratory System Infections II A.Ç. Büke	**Group C IL** / **Group D IL** / **Group B ICP** / **Group A Small Group Study** Scientific Project	**Group C IL** / **Group D IL** / **Group B Small Group Study** Scientific Project / **Group A ICP**	
11.00- 11.50	**Lecture** Tobacco Control and Chronic Non-Communicable Diseases IV R.E. Sezer	**Lecture** Bloodstream Invasion & Sepsis II M. Sönmezoğlu			
12.00- 12.50	**Lecture** Epidemiology, Prevention and Control of Chronic Non-Communicable Respiratory Diseases R.E. Sezer	**Lecture** Cardiac Infections M. Sönmezoğlu	**Independent Learning**	**Independent Learning**	
12.50- 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Hypersensitivity Reactions G. Yanıkkaya Demirel	**Lecture** Chronic Restrictive Pulmonary Diseases I I.D. Ekici	**Multidisciplinary Case Discussion Panel**	**Independent Learning**	**Independent Learning**
15.00- 15.50	**Lecture** Hypersensitivity Reactions G. Yanıkkaya Demirel	Chronic Restrictive Pulmonary Diseases II I.D. Ekici	**Multidisciplinary Case Discussion Panel**		
16.00- 16.50	**Lecture** Congenital Heart Disease I I.D. Ekici	**Lecture** Pharmacology and Toxicology of Tobacco F. Arıcıoğlu	**Independent Learning**		
17.00-17.50	**Lecture** Congenital Heart Disease II I.D. Ekici	**Independent Learning**	**Independent Learning**		

COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK VII /11-15 Dec 2017

	Monday 11-Dec-2017	Tuesday 12-Dec-2017	Wednesday 13-Dec-2017	Thursday 14-Dec-2017	Friday 15-Dec-2017
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
12.50- 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	**Program Evaluation Session** Committee II Coordination Committee Members
15.00- 15.50					Independent Learning
16.00- 16.50					
17.00-17.50					

COMMITTEE III - GASTROINTESTINAL SYSTEM

DISTRIBUTION of LECTURE HOURS

December 18, 2017 - January 12, 2018

COMMITTEE DURATION: 4 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
	GASTROENTEROHEPATOLOGY	GE	24				**24**
	PATHOLOGY	PT	15		1x3=3 (2 Groups)		**18**
	PHARMACOLOGY	PC	5				**5**
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	4				**4**
	PUBLIC HEALTH	PH	3				**3**
	INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	IDCM	4				**4**
	IMMUNOLOGY	IMM	2				**2**
	PHYTOTHERAPY	PHY	3				**3**
	PATHOPHYSIOLOGY	PP	2				**2**
	BIOSTATISTICS	BS	3				**3**
	FAMILY MEDICINE	FM	2				**2**
	PEDIATRICS	PED	1				**1**
	PEDIATRIC SURGERY	PEDS	1				**1**
	RADIOLOGY	RAD	1				**1**
	MEDICAL GENETICS	MG	2				**2**
	SURGERY	GS	1				**1**
	EMERGENCY MEDICINE	EM	1				**1**
	INTERDISCIPLINARY	MCDP				2	2
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			1X3=3 (4 Groups)		**3**
TOTAL			**74**		**6**	**2**	**82**

Coordination Committee

HEAD	Meltem Ergün, MD, Assoc. Prof.
SECRETARY	Atakan Yeşil, MD, Assoc. Prof
MEMBER	Ferda Özkan, MD, Prof.
MEMBER	Meltem Uğraş, MD, Assoc. Prof.
MEMBER	Barış Ata Borsa, Asst. Prof.

COMMITTEE III - GASTROINTESTINAL SYSTEM
LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
GASTROENTEROHEPATOLOGY	Meltem Ergün, MD, Assoc. Prof. Atalay Yeşil, MD, Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD, Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Feyza Arıcıoğlu, PhD, Prof.
PUBLIC HEALTH	Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Asst. Prof
BIOMEDICAL ETHICS & DEONTOLOGY	Hakan Ertin, MD, Assoc. Prof. Rainer Brömer, PhD, Assoc. Prof.
INFECTIOUS DISEASES AND MEDICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof. A.Çağrı Büke, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PHYTOTHERAPY	Erdem Yeşilada, PhD, Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Assoc.Prof.
BIOISTATISTICS	Çiğdem Altunok, PhD, Asst. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Asst Prof.
PEDIATRICS	Meltem Uğraş, MD, Prof.
PEDIATRIC SURGERY	Selami Sözübir, MD, Prof.
GENERAL SURGERY	Onur Yaprak, MD, Assoc. Prof.
RADIOLOGY	Osman Melih Topçuoğlu, MD
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.
SCIENTIFIC PROJECTS	Gülderen Yanıkkaya Demirel, MD, Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Zehra Eren, MD, Assoc. Prof. Atakan Yeşil, MD, Assoc. Prof. Orhan Önder Ören, MD, Assoc. Prof. Güldal İzbırak, MD, Assoc. Prof. Serdar Özdemir, MD, Asst. Prof.

COMMITTEE III - GASTROINTESTINAL SYSTEM

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of gastrointestinal system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to gastrointestinal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
8. ***to convey*** knowledge on phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
9. ***to convey*** knowledge on biostatistical analysis of association between variables,
10. ***to convey*** necessary knowledge on legal regulations and ethical principles for end-of-life decisions,
11. ***to equip with*** basic and advanced clinical skills (approach to patient with gastrointestinal clinical condition-C4) required at primary health care service level.
12. ***to convey*** knowledge on use of phytotherapy in an evidence based manner and drug interactions in phytotherapy,

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of gastrointestinal system,

2.0. ***explain*** etiopathogenesis of clinical conditions (infections, nutritional disorders, bleedings, clinical conditions related to gastrointestinal organs) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

3.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

4.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
5.0. ***explain*** importance of healthy nutrition, principles of balanced diet, and measurement of nutritional status,
6.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
7.0. at multi-system level and/or related to gastrointestinal system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

7.1. practice of history taking and physical examination (gastrointestinal-C4)
7.2. evaluation of emergency case (acute abdominal pain-C4)
7.3. approach to healthy individual or patient (diarrhea-C4)
7.4. laboratory tests/examinations
7.5. imaging tests/examinations (scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumors-C4)
7.6. point of care testing
7.7. making preliminary diagnosis or definitive diagnosis decision
7.8. making non-intervention or intervention decision
7.9. practicing non-intervention or intervention
7.10. referral/transport of healthy individual or patient

8. ***list*** differences of gastrointestinal clinical conditions that may occur in children,
9. ***explain*** liver transplantation (indications, contraindications, conditions, risks, methods, patient care, results and monitorization),
10. ***explain*** pharmacology of drugs (agents used in the treatment of peptic ulcer, emetic and antiemetic agents, laxatives) that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
11. ***explain*** genetics of gastrointestinal system,
12. ***explain*** phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
13. ***define*** biostatistical analysis of association between variables,
14. ***tell*** legal regulations and ethical principles for end-of-life decisions,
15. ***perform*** basic clinical skills, practiced on phantom models and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with gastrointestinal clinical condition-C4), required at primary health care service.
16. ***to convey*** knowledge on use of phytotherapy in an evidence based manner and drug interactions in phytotherapy.

COMMITTEE III - GASTROINTESTINAL SYSTEM
COMMITTEE ASSESSMENT MATRIX

PHASE III
COURSE: MD 302 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT: COMMITTEE III - GASTROINTESTINAL SYSTEM

QUESTION DISTRIBUTION TABLE

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	GE	M. Ergün A. Yeşil	29	7	7	**43**
2.0.,6.0.	PT	I. D. Ekici	18	5	5	**28**
2.0.,6.0.,7.4.		F. Özkan				
2.0, 6.0, 7.4		A.S. Çöloğlu				
10.0.	PC	E. Genç	6	2	2	**10**
10.0.		F. Arıcıoğlu				
3.0.,4.0.,5.0.	PH	R.E. Sezer	4	1	1	**6**
3.0.,4.0.,5.0.		H.A.Taşyıkan				
	IMM	G. Y. Demirel	2	1	1	**4**
14.0.	BED	H. Ertin/ R. Brömer	5	1	1	**7**
2.0.,3.0.,4.0.,6.0.,7.0.	IDCM	M. Sönmezoğlu A.Ç. Büke	6	2	2	**10**
13.0.	BS	Ç. Altunok	4	1	1	**6**
12.0	PHR (PHY)	E. Yeşilada	4	0	0	**4**
2.0.,6.0.	PP	M. Kaçar	2	1	1	**4**
7.3.	FM	G. İzbırak	2	1	1	**4**
7.3.		Ö. Tanrıöver				
5.0.	PED	M. Uğraş	2	0	0	**2**
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	PEDS	S. Sözübir	1	0	0	**1**
7.5.	RAD	N. Taşdelen	1	0	0	**1**
11.0.	MG	A.Ç. Kuşkucu	2	1	1	**4**
9.0.	GS	O. Yaprak	1	0	0	**1**
2.0.,3.0.,4.0.,6.0.,7.3.	EM	F. Çelikmen	1	0	0	**1**
TOTAL			**90**	**23**	**23**	**136**

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	GE	M. Ergün	3	-	-	3
2.0.,6.0.,7.4.	PT	F. Özkan/ I.D. Ekici	2	-	-	2
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 pts; pts:** Points
*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.
MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
****23** out of 200 FE and ICE MCQs will be from Committee III (Each question is of worth **0.5** pts).

COMMITTEE III - GASTROINTESTINAL SYSTEM
WEEK I / 18-22 Dec 2017

	Monday 18-Dec-2017	Tuesday 19-Dec-2017	Wednesday 20-Dec-2017	Thursday 21-Dec-2017	Friday 22-Dec-2017
09.00- 09.50	**Independent Learning**	**Lecture** Oral Pathology F. Özkan	**Lecture** Pathology of Stomach I F. Özkan	**ICP-CSL** (History taking and physical examination of gastrointestinal system) Z.Eren / S. Özdemir / G.İzbırak	**Lecture** Pathology of Liver I F. Özkan
10.00- 10.50	**Lecture** Semiology I M. Ergün	**Lecture** Pathology of Esophagus I F. Özkan	**Lecture** Pathology of Stomach II F. Özkan	**Group A ICP** / **Group B Small Group Study** Scientific Project / **Group C IL** / **Group D IL**	**Lecture** Pathology of Liver I F. Özkan
11.00- 11.50	**Lecture** Semiology II M. Ergün	**Lecture** Pathology of Esophagus II F. Özkan	**Lecture** Pathology of Intestinal Diseases I F. Özkan		**Lecture** Acute Gastroenteritis M. Sönmezoğlu
12.00- 12.50	**Lecture** Pathophysiology of Gastro–intestinal Disorders I M. Kaçar	**Lecture** Laxatives F. Arıcıoğlu	**Lecture** Pathology of Intestinal Diseases II F. Özkan	**Independent Learning**	**Lecture** Hepatitis I M. Sönmezoğlu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pathophysiology of Gastro–intestinal Disorders II M. Kaçar	**Lecture** Comparing Groups-countinous Data I Ç. Altunok	**Lecture** Approach to the Patient with Abdominal Pain Regarding to Primary Care G. İzbırak	**Lecture** Malabsorbtion A. Yeşil	**Lecture** Food Poisoning A.Ç. Büke
15.00- 15.50	**Lecture** Comparing Groups-categorical Data Ç. Altunok	**Lecture** Comparing Groups-countinous Data II Ç. Altunok	**Lecture** Approach to the Patient with Diarrhea Regarding to Primary Care Ö. Tanrıöver	**Lecture** Inflammatory Bowel Disease A. Yeşil	**Independent Learning**
16.00- 16.50	**Lecture** The Ethics of Testing and Screening Ethics Lecturer	**Lecture** Clinical Approach to the Patient with Acute Abdominal Pain S. Sarıkaya	**Independent Learning**	**Lecture** Functional GI Disorders & Irritable Bowel Disease A. Yeşil	**Independent Learning**
17.00-17.50	**Lecture** The Ethics of Dealing with Infectious Diseases Ethics Lecturer	**Lecture** Gastrointestinal Bleedings in Children S. Sözübir	**Independent Learning**	**Lecture** Tumors of Eusophagus, Stomach and Small Intestine A. Yeşil	**Independent Learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE III - GASTROINTESTINAL SYSTEM
WEEK II / 25-29 Dec 2017

	Monday 25-Dec-2017	Tuesday 26-Dec-2017	Wednesday 27-Dec-2017	Thursday 28-Dec-2017	Friday 29-Dec-2017
09.00- 09.50	**Lecture** Gastritis and Helicobacter Pylori M. Ergün	**Lecture** Pathology of Liver & Biliary System I I. D. Ekici	**Lecture** Hepatitis II M. Sönmezoğlu	**ICP-CSL** (History taking and physical examination of gastrointestinal system) Z. Eren / S. Özdemir / G.İzbırak	**ICP-CSL** (History taking and physical examination of gastrointestinal system) A.Yeşil / S. Özdemir / G.İzbırak
10.00- 10.50	**Lecture** Gastroeusophegeal Reflux (GE) and Esophageal Motility Disorder M. Ergün	**Lecture** Pathology of Liver & Biliary System II I. D. Ekici	**Lecture** Jaundice M. Ergün	**Group D** Small Group Study Scientific Project / **Group C ICP** / **Group A IL** / **Group B IL**	**Group A IL** / **Group B IL** / **Group D ICP** / **Group C** Small Group Study Scientific Project
11.00- 11.50	**Lecture** Agents used in the Treatment of Peptic Ulcer I E. Genç	**Lecture** Pathology of Liver & Biliary System III I. D. Ekici	**Lecture** Chronic Viral Hepatitis M. Ergün		
12.00- 12.50	**Lecture** Agents used in the Treatment of Peptic Ulcer II E. Genç	**Lecture** Pathology of Liver & Biliary System IV I. D. Ekici	**Lecture** Cirrhosis and Portal Hypertension M. Ergün	**Lecture** Pathology of Appendix & Peritoneum F. Özkan	**Lecture** Premalignant Lesion of the Colon M. Ergün
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Peptic Ulcer Disease M. Ergün	**Pathology Laboratory** (Gastrointestinal System) F. Özkan/ I.D. Ekici / **Group A** / **Group B IL**	**Lecture** Public Health and Nutrition I R.E. Sezer	**Pathology Laboratory** (Gastrointestinal System) F. Özkan/ I.D. Ekici / **Group A** / **Group B IL**	**Lecture** Steatohepatitis A. Yeşil
15.00- 15.50	**Lecture** Autoimmune Hepatitis M. Ergün	**Group A IL** / **Group B**	**Lecture** Public Health and Nutrition II R.E. Sezer	**Group A IL** / **Group B**	**Lecture** Acute Liver Failure A. Yeşil
16.00- 16.50	**Lecture** Immunologic Tolerance and Autoimmunity G. Yanıkkaya Demirel		**Independent Learning**		**Lecture** Disease of the Bile Duct and Gall Bladder A. Yeşil
17.00-17.50	**Lecture** Immunologic Tolerance and Autoimmunity G. Yanıkkaya Demirel	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Abdominal Pain A. Yeşil

COMMITTEE III - GASTROINTESTINAL SYSTEM
WEEK III / 1-5 Jan 2018

<table>
<tr><th></th><th>Monday
1-Jan-2018</th><th>Tuesday
2-Jan-2018</th><th>Wednesday
3-Jan-2018</th><th colspan="4">Thursday
4-Jan-2018</th><th>Friday
5-Jan-2018</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">NEW YEAR
HOLIDAY</td><td>Lecture
Antiemetic Agents
F. Arıcıoğlu</td><td>Lecture
Toxic Hepatitis
M. Ergün</td><td colspan="4">ICP-CSL
(History taking and physical examination of gastrointestinal system)
A. Yeşil / S. Özdemir / G.İzbırak</td><td>Lecture
Transplantation of Liver
O. Yaprak</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Digestive & Antidiarrheal Drugs
F. Arıcıoğlu</td><td>Lecture
Mass Lesions of the Liver
M. Ergün</td><td rowspan="2">Group C
IL</td><td rowspan="2">Group D
IL</td><td rowspan="2">Group A
Small Group Study
Scientific Project</td><td rowspan="2">Group B</td><td>Lecture
Radiology of Gastrointestinal System
O.M.Topçuoğlu</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Ethics of Dealing with Addiction
Ethics Lecturer</td><td>Lecture
Complex Diseases-Inherited Gastrointestinal System Disorders
A.Ç. Kuşkucu</td><td>Multidisciplinary Case Discussion Panel</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Ethics of Elective Interventions
Ehics Lecturer</td><td>Lecture
Complex Diseases-Inherited Gastrointestinal System Disorders
A.Ç. Kuşkucu</td><td colspan="4">Independent Learning</td><td>Multidisciplinary Case Discussion Panel</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="8">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="4">NEW YEAR
HOLIDAY</td><td>Lecture
Phytotherapy-IV
E. Yeşilada</td><td>Lecture
Clinical Nutrition
M. Uğraş</td><td colspan="4">Lecture
Wilson Disease and Hemochromatisis
A. Yeşil</td><td rowspan="4">Independent learning</td></tr>
<tr><td>15.00- 15.50</td><td>Lecture
Phytotherapy-V
E. Yeşilada</td><td>Lecture
Alcoholic Liver Disease
A. Yeşil</td><td colspan="4">Lecture
Acute and Chronic Pancreatitis
A. Yeşil</td></tr>
<tr><td>16.00- 16.50</td><td>Lecture
Phytotherapy-VI
E. Yeşilada</td><td>Lecture
Epidemiology, Prevention and Control of Obesity
H.A. Taşyıkan</td><td colspan="4">Lecture
Tumors of the Bile Ducts and Pancreas
A. Yeşil</td></tr>
<tr><td>17.00-17.50</td><td>Independent Learning</td><td>Independent learning</td><td colspan="4">Independent learning</td></tr>
</table>

COMMITTEE III - GASTROINTESTINAL SYSTEM
WEEK IV / 8-12 Jan 2018

<table>
<tr><th></th><th>Monday
8-Jan-2018</th><th>Tuesday
9-Jan-2018</th><th>Wednesday
10-Jan-2018</th><th>Thursday
11-Jan-2018</th><th>Friday
12-Jan-2018</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">Independent learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td></tr>
<tr><td>12.00- 12.50</td><td rowspan="2">Independent learning</td><td rowspan="2">Independent Learning</td><td rowspan="2">Independent Learning</td><td rowspan="2">Independent Learning</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="4">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="3">Independent learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td>Program Evaluation Session
Committee III
Coordination Committee
Members</td></tr>
<tr><td>15.00 -15.50</td><td rowspan="3">Independent Learning</td></tr>
<tr><td>16.00 - 16.50</td></tr>
<tr><td>17.00 - 17.50</td><td></td><td></td><td></td><td></td><td></td></tr>
</table>

COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS

DISTRIBUTION of LECTURE HOURS

January 29, 2018 – March 23, 2018

COMMITTEE DURATION: 8 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	PATHOLOGY	PT	32		1x2=2 (2 Groups)		**34**
	OBST & GYNEC	OBS-GYN	16				**16**
	ENDOCRINOLOGY	END	15				**15**
	IMMUNOLOGY	IM	2				**2**
	PHARMACOLOGY	PC	14				**14**
	MEDICAL GENETICS	MG	6				**6**
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	5		2x2=4 (2 Groups)		**9**
	PATHOPHYSIOLOGY	PP	7				**7**
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	4				**4**
	PUBLIC HEALTH	PH	5				**5**
	FAMILY MEDICINE	FM	5				**5**
	PEDIATRICS	PED	6				**6**
	BIOSTATISTICS	BS	3				**3**
	PHYTOTHERAPY	PHR (PHY)	2				**2**
	RADIOLOGY	RAD	2				**2**
	HISTOLOGY	HST	1				**1**
	UROLOGY	URO	7				**7**
	NEPHROLOGY	NE	13				**13**
	PEDIATRIC SURGERY	PED-S	1				**1**
	GENERAL SURGERY	GS	1				**1**
	SCIENTIFIC PROJECTS- III	SP	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			1x3=3 (4 Groups) 1x2=2 (4 Groups) 1x3=3 (4 Groups)		**8**
TOTAL			**148**		**14**	**2**	**164**

Coordination Committee

HEAD	Hasan Aydın, MD, Prof.
SECRETARY	Rukset Attar, MD, Assoc. Prof.
MEMBER	Gülçin Kantarcı, MD, Prof.
MEMBER	Zehra Eren, MD, Assoc. Prof.
MEMBER	Ahmet Tunç Özdemir, MD, Assoc. Prof.

COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
PATHOLOGY	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD, Prof.
OBSTETRICS and GYNECOLOGY	N. Cem Fıçıcıoğlu, MD, Prof. Meral Aban, MD, Prof. Selçuk Özden, MD, Prof. Rukset Attar, MD, Assoc. Prof. Gazi Yıldırım, MD, Assoc. Prof.
ENDOCRINOLOGY	Hasan Aydın, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Feyza Arıcıoğlu, PhD, Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	Meral Sönmezoğlu, MD Prof. A.Çağrı Büke, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
BIOMEDICAL ETHICS&DEONTOLOGY	Hakan Ertin, MD, Assoc. Prof. Rainer Brömer, PhD, Assoc. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof. Hale Arık Taşyıkan, MD, Asst. Prof.
FAMILY MEDICINE	Özlem Tanrıöver, MD, Assoc. Prof. Ayşe Arzu Akalın, MD, Asst. Prof.
PEDIATRICS	Filiz Bakar, MD, Prof. Mustafa Berber, MD, Asst. Prof. Fatma Tuba Coşkun, MD Endi Romano, MD
BIOSTATISTICS	Çiğdem Altunok, PhD, Asst. Prof.
RADIOLOGY	Ayşegül Sarsılmaz, MD, Asst. Prof. O. Melih Topçuoğlu MD, Asst. Prof.
PHYTOTHERAPY	Erdem Yeşilada, MD, Prof.
HISTOLOGY & EMBRYOLOGY	Oya Alagöz, MD, Asst. Prof.
NEPHROLOGY	Gülçin Kantarcı, MD, Prof. Zehra Eren, MD, Assoc. Prof.
UROLOGY	Faruk Yencilek, MD, Prof. Ahmet Tunç Özdemir, MD, Assoc. Prof. Hasbey Hakan Koyuncu, MD, Assoc. Prof.
PEDIATRIC SURGERY	Selami Sözübir, MD, Prof.
GENERAL SURGERY	Onur Yaprak, MD, Assoc. Prof. Altan Alim, MD
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Filiz Bakar, MD, Prof. Rukset Attar, MD, Assoc. Prof. Gazi Yıldırım, MD, Assoc. Prof. Özlem Tanrıöver, MD, Assoc. Prof. Ayşe Arzu Akalın, MD, Asst. Prof. Mustafa Berber, MD, Asst. Prof.

COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS

AIMS and LEARNING OBJECTIVES

ENDOCRINE & REPRODUCTIVE SYSTEMS

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, embryology, histology and physiology of endocrine and reproductive systems,
2. ***to convey*** knowledge on health care service practices related to reproductive care,
3. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
4. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
5. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,
6. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
7. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to endocrine and reproductive systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
8. ***to convey*** knowledge on pharmacology of drugs that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,
9. ***to convey*** knowledge on genetics of endocrine and reproductive systems,
10. ***to convey*** knowledge on phytotherapeutic agents that are effective on endocrine system or on clinical conditions involving endocrine system,
11. ***to convey*** knowledge on design and biostatistical analysis of survival research,
12. ***to convey*** knowledge on legal regulations and ethical principles related to reproductive care,
13. ***to equip with*** basic and advanced clinical skills (*normal spontaneous vaginal delivery on phantom model-C5*) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***recall*** anatomy, embryology, histology and physiology of endocrine and reproductive systems,
2.0. ***explain*** physiology of normal spontaneous vaginal delivery,
3.0. ***define*** practice of reproductive care,
4.0. ***explain*** etiopathogenesis of clinical conditions (menstrual cycle/developmental conditions/congenital and sexually transmitted infections) which are frequent in community and/or

pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,

5.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,

6.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,

7.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,

8.0. at multi-system level and/or related to endocrine and reproductive systems,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

8.1. practice of history taking and physical examination (gynecological-C5, breast-C5)

8.2. evaluation of emergency case

8.3. approach to healthy individual or patient (pregnancy-C5)

8.4. laboratory tests/examinations (venous blood collection-C5, throat swab specimen-C5, sputum sample collection-C5, thyroid function tests-C5, diabetes tests-C5, rapid screening [antigen/antibody] tests-C5, throat culture-C5, sputum culture-C5)

8.5. imaging tests/examinations (radiological examinations in gynecology-C5, breast imaging-C5, radioisotope imaging of thyroid and parathyroid-C5)

8.6. point of care testing (diabetes tests-C5, rapid screening [antigen/antibody] tests-C5)

8.7. making preliminary diagnosis or definitive diagnosis decision

8.8. making non-intervention or intervention decision

8.9. practicing non-intervention or intervention

8.10. referral/transport of healthy individual or patient

9.0. ***explain*** pharmacology of drugs (hypothalamic and pituitary hormones, drugs effecting functions and action of oxytocin and ADH, thyroid and antithyroid drugs, adrenocortical hormones and drugs, insulin and oral antidiabetic drugs, estrogens, progestines and inhibitors) that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,

10.0. ***explain*** genetics of endocrine and reproductive systems,

11.0. ***explain*** mechanisms of action for phytotherapeutic agents that are effective on endocrine system or in clinical conditions related to endocrine system,

12.0. ***define*** design and biostatistical analysis of survival research,

13.0. ***explain*** legal regulations and ethical principles related to reproductive care,

14.0. ***perform*** basic clinical skills, practiced on phantom models (normal spontaneous vaginal delivery-C5), and advanced clinical skills, practiced on simulated/standardized patients required at primary health care service.

URINARY SYSTEM

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of urinary system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,
5. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to urinary system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the** level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
8. ***to convey*** knowledge on genetics of urinary system,
9. ***to convey*** knowledge on phytotherapeutic agenst that are effective on urinary system or on clinical conditions involving urinary system,
10. ***to convey*** knowledge on use of biostatistical software and presentation of results,
11. ***to convey*** knowledge on legal regulations and ethical principles related to reproductive care,
12. ***to equip with*** basic and advanced clinical skills *(gynecological examination-C6, "Pap-smear" collection-C6, intrauterine device placement-C6, breast examination-C6, physical examination in neonate, infant and prepubertal/pubertal child-C6)* required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1. ***recall*** anatomy, histology and physiology of urinary system,
2. ***explain*** etiopathogenesis of clinical conditions (renal hemodynamics, acid-base equilibrium, renal clinical conditions, urinary system stones, urinary system infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
3. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,
5. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,

6. at multi-system level and/or related to urinary system,
   - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
   - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
   - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

6.1. practice of history taking and physical examination (neonatal, prepubertal/pubertal-C6)
6.2. evaluation of emergency case (urological emergencies-C6)
6.3. approach to healthy individual or patient (urethral-vaginal-cervical discharge/swab specimen-C6, fecal specimen collection-C6)
6.4. laboratory tests/examinations (urethral-vaginal-cervical discharge culture-C6, fecal culture-C6)
6.5. imaging tests/examinations (uroradiology-C6, renal scintigraphy (GFR, ERPF, Renogram)-C6)
6.6. point of care testing
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient

7. ***explain*** pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
8. ***explain*** pharmacology of androgens and anabolic steroids, and drugs that affect bone mineral homeostasis,
9. ***explain*** genetics of urinary system,
10. ***explain*** mechanisms of action for action for phytotherapeutic agents that are effective on urinary system or in clinical conditions related to urinary system,
11. ***define*** use of biostatistical software and presentation of results,
12. ***perform*** basic clinical skills, practiced on phantom models, and advanced clinical skills, practiced on simulated/standardized patients (gynecological examination-C6, “Pap-smear” collection-C6, intrauterine device placement-C6, breast examination-C6, physical examination in neonate, infant and prepubertal/pubertal child-C6), required at primary health care service.

COMMITTEE IV - ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS
COMMITTEE ASSESSMENT MATRIX

PHASE III
COURSE: MD 302 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT: COMMITTEE IV – ENDOCRINE, REPRODUCTIVE & URINARY SYSTEMS

QUESTION DISTRIBUTION TABLE

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
1.0, 4.0, 7.0, 8.4	PT	F. Özkan	20	10	10	**40**
1.0, 4.0, 7.0, 8.4		I.D. Ekici				
1.0, 4.0, 7.0, 8.4		A. Sedat Çöloğlu				
1.0-8.0	OBS-GYN	C. Fıçıcıoğlu	10	5	5	**20**
1.0-8.0		S.Özden				
1.0-8.0		R. Attar				
1.0-8.0		G. Yıldırım				
1.0, 4.0-8.0	END	H. Aydın	9	5	5	**19**
	IMM	G.Y. Demirel	1	1	1	**3**
	NE	G. Kantarcı	8	4	4	**16**
		Z. Eren				
	URO	F. Yencilek	4	2	2	**8**
		A.T. Özdemir				
		H.H. Koyuncu				
	GS	O. Yaprak	1	0	0	**1**
		A. Alim				
	PED-S	S. Sözübir	1	0	0	**1**
9.0	PC	E. Genç	9	4	4	**17**
		F. Arıcıoğlu				
4.0, 7.0	PP	M. Kaçar	4	2	2	**8**
10.0	BED	H. Ertin / R. Brömer	2	1	1	**4**
5.0, 6.0	PH	R.E. Sezer	3	2	2	**7**
5.0, 6.0		H. A. Taşyıkan				
6.0, 8.0,8.1, 8.3	FM	A. Akalın	3	2	2	**7**
8.3		Ö. Tanrıöver				
12.0	BS	Ç. Altunok	2	1	1	**4**
4.0, 5.0, 6.0, 7.0, 8.0	IDCM	M. Sönmezoğlu	3	2	2	**7**
4.0, 5.0, 6.0, 7.0, 8.4		A.Ç. Büke				
1.0, 4.0-8.0	PED	F. Bakar / E. Romano	3	2	2	**7**
		M. Berber/ T. Coşkun				
10.0	MG	A. Ç. Kuşkucu	4	2	2	**8**
	PHR (PHY)	E. Yeşilada	1	0	0	**1**
8.5,	RAD	N. Taşdelen	1	0	0	**1**
1.0	HST	O. Akçin	1	0	0	**1**
TOTAL			**90**	**45**	**45**	**180**

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0, 4.0-8.0	END	H. Aydın	1	-	-	**1**
1.0-8.0	OBS-GYN		1	-	-	**1**
	NE	G. Kantarcı / Z. Eren	1	-	-	**1**
	URO	A. T. Özdemir / H. H. Koyuncu	1	-	-	**1**
1.0, 4.0, 7.0, 8.4	PT	F. Özkan	1	-	-	**1**
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**
*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.
MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
pts: Points
****45** out of 200 FE and ICE MCQs will be from Committee IV (Each question is of worth **0.5** pts).

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEM
WEEK I / 29 Jan – 2 Feb 2018

	Monday 29-Jan-2018	Tuesday 30-Jan-2018	Wednesday 31-Jan-2018	Thursday 1-Feb-2018	Friday 2-Feb-2018
09.00- 09.50	**Independent Learning**	**Lecture** Pathology of Endocrine System: Introduction I.D. Ekici	**ICP-CSL** (Follow-up of pregnancy & stages of normal labour & Gynecological examination, PAP smear obtaining) R. Attar / G. Yıldırım	**Independent Learning**	**Lecture** Thyroid and Antithyroid Drugs I E. Genç
10.00- 10.50	**Lecture** Pathophysiology of Endocrine System Diseases I M. Kaçar	**Lecture** Pathology of Pituitary Gland I I.D. Ekici	**Group A ICP** / **Group B Small Group Study** Scientific Project / **Group D ICP** / **Group D IL**	**Independent Learning**	**Lecture** Thyroid and Antithyroid Drugs II E. Genç
11.00- 11.50	**Lecture** Pathophysiology of Endocrine System Diseases II M. Kaçar	**Lecture** Pathology of Pituitary Gland II I.D. Ekici		**Independent Learning**	**Lecture** Imaging of Thyroid Glands A. Sarsılmaz
12.00- 12.50	**Lecture** Pathophysiology of Endocrine System Diseases III M. Kaçar	**Lecture** Introduction to Endocrine Pharmacology E. Genç	**Independent Learning**	**Independent Learning**	**Lecture** Calcium Metabolism H. Aydın
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Introduction to Endocrinology H. Aydın	**Lecture** Hypothalamic and Pituitary Hormones I F. Arıcıoğlu	**Lecture** Thyroid Function Tests H. Aydın	**Lecture** Pathology of Adrenal Gland I F. Özkan	**Lecture** Hypercalcemic Diseases H. Aydın
15.00- 15.50	**Lecture** Hyperfunctioning Disorders of Anterior Pituitary Gland H. Aydın	**Lecture** Hypothalamic and Pituitary Hormones II F. Arıcıoğlu	**Lecture** Thyroid Disorders H. Aydın	**Lecture** Pathology of Adrenal Gland II F. Özkan	**Lecture** Pathology of Thyroid & Parathyroid I F. Özkan
16.00- 16.50	**Lecture** Disorders of Posterior Pituitary Gland H. Aydın	**Lecture** Delivery of Family Planning Services I A. Akalın	**Lecture** Immunology of reproduction G. Yanıkkaya Demirel	**Independent Learning**	**Lecture** Pathology of Thyroid & Parathyroid II F. Özkan
17.00-17.50	**Lecture** Hypopituatirism H. Aydın	**Lecture** Delivery of Family Planning Services II A. Akalın	**Lecture** Immunology of reproduction G. Yanıkkaya Demirel	**Independent Learning**	**Independent Learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK II / 5-9 Feb 2018

	Friday 5-Feb-2018	Tuesday 6-Feb-2018	Wednesday 7-Feb-2018	Thursday 8-Feb-2018	Friday 9-Feb-2018
09.00- 09.50	**Lecture** Hypocalcemic Diseases H. Aydın	**Lecture** Obesity H. Aydın	**Lecture** Insulin and Oral Antidiabetic Drugs I E. Genç	**ICP-CSL** (Follow-up of pregnancy & stages of normal labour & Gynecological examination, PAP smear obtaining) R. Attar / G. Yıldırım	**Lecture** The Gynecological History and Examination G. Yıldırım
10.00- 10.50	**Lecture** Adrenal Disorders H. Aydın	**Lecture** Diffuse Hormonal Systems and Endocrine Tumor Syndromes H. Aydın	**Lecture** Insulin and Oral Antidiabetic Drugs II E. Genç	**Group AS** Small Group Study Scientific Project / **Group B ICP** / **Group C IL** / **Group D IL**	**Lecture** Endometriosis & Adenomyosis G. Yıldırım
11.00- 11.50	**Lecture** Hypoglycemia H. Aydın	**Lecture** Introduction to Diabetes Mellitus H. Aydın	**Lecture** Chromosomal Disorders I A. Ç. Kuşkucu		**Lecture** Pathology of Cervix Uteri I F. Özkan
12.00- 12.50	**Lecture** Congenital Adrenal Hyperplasia M. Berber	**Lecture** Clinical and Laboratory Findings of Diabetes Mellitus H. Aydın	**Lecture** Chromosomal Disorders II (Sex Chromosomes and their Abnormalities) A. Ç. Kuşkucu	**Independent Learning**	**Lecture** Pathology of Cervix Uteri II F. Özkan
12.50-14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pathology of Pancreas I I.D. Ekici	**Lecture** Conditions affecting Vulva & Vagina M. Aban	**Lecture** Pathophysiology of Reproductive System Diseases I M. Kaçar	**Lecture** Pathology of Breast I F. Özkan	**Lecture** Pathology of Vulva & Vagina F. Özkan
15.00- 15.50	**Lecture** Pathology of Pancreas II I.D. Ekici	**Independent Learning**	**Lecture** Pathophysiology of Reproductive System Diseases II M. Kaçar	**Lecture** Pathology of Breast II F. Özkan	**Independent Learning**
16.00- 16.50	**Lecture** Adrenocortical Hormones and Drugs I E. Genç	**Independent Learning**	**Lecture** Puerperal Infections S. Özden	**Independent Learning**	**Independent Learning**
17.00-17.50	**Lecture** Adrenocortical Hormones and Drugs II E. Genç	**Independent Learning**	**Lecture** Normal and Abnormal Labor S. Özden	**Independent Learning**	**Independent Learning**

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS
WEEK III / 12-16 Feb 2018

	Monday 12-Feb-2018	Tuesday 13-Feb-2018	Wednesday 14-Feb-2018	Thursday 15-Feb-2018	Friday 16-Feb-2018
09.00-09.50	**Lecture** Genetic Disorders of Gonadal Development A. Ç. Kuşkucu	**Lecture** Relation Between Two Variables I Ç. Altunok	**Lecture** Prenatal Genetic Diagnosis A. Ç. Kuşkucu	**ICP-CSL** (Follow-up of pregnancy & stages of normal labour & Gynecological examination, PAP smear obtaining) R. Attar / G. Yıldırım	**Lecture** Embryology O. Alagöz
10.00-10.50	**Lecture** Genetic Disorders of Gonadal Development A. Ç. Kuşkucu	**Lecture** Relation Between Two Variables II Ç. Altunok	**Lecture** Genetic Counseling A. Ç. Kuşkucu	**Group A IL** / **Group B IL** / **Group C ICP** / **Group D Small Group Study** Scientific Project	**Lecture** Reproductive, Maternal and Child Health I H. A. Taşyıkan
11.00-11.50	**Lecture** Pathology of Pregnancy & Placenta F. Özkan	**Lecture** Antenatal Care S. Özden	**Lecture** Normal Pubertal Development M. Berber B. Haliloğlu		**Lecture** Reproductive, Maternal and Child Health II H. A. Taşyıkan
12.00-12.50	**Lecture** Pathology of Uterus I F. Özkan	**Lecture** Disorders of Early Pregnancy (Miscarriage; Ectopic; GTD) S. Özden	**Lecture** Pubertal Disorders M. Berber B. Haliloğlu	**Independent Learning**	**Lecture** Reproductive, Maternal and Child Health III H. A. Taşyıkan
12.50-14.00	**LUNCH BREAK**				
14.00-14.50	**Lecture** Pathology of Uterus II F. Özkan	**Lecture** Medical History for Breast Diseases in Primary Care & Clinical Breast Examination A. Akalın	**Lecture** The Menstrual Cycle and Disorders of the Menstrual Cycle R. Attar	**ICP-CSL** (Follow-up of pregnancy & stages of normal labour & Gynecological examination, PAP smear obtaining) R. Attar/ G. Yıldırım	**Lecture** Pathology of Ovary I F. Özkan
15.00-15.50	**Microbiology Laboratory** (Laboratory Tests-II) **Group A** / **Group B IL** / **Group C & D IL**	**Microbiology Laboratory** (Laboratory Tests-II Microbiology nstructors) **Group C** / **Group D IL** / **Group A & B IL**	**Lecture** Normal and Abnormal Sexual Development & Puberty R. Attar	**Group A IL** / **Group B IL** / **Group C Small Group Study** Scientific Project / **Group D ICP**	**Lecture** Pathology of Ovary II F. Özkan
16.00-16.50	**Group A IL** / **Group B**	**Group C IL** / **Group D**	**Lecture** Estrogens, Progestines and Inhibitors I F. Arıcıoğlu		**Lecture** Pathology of Treponemal Infections F. Özkan
17.00-17.50	**Independent Learning**	**Independent learning**	**Lecture** Estrogens, Progestines and Inhibitors II F. Arıcıoğlu	**Independent Learning**	**Independent Learning**

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK IV / 19-23 Feb 2018

	Monday 19-Feb-2018	Tuesday 20-Feb-2018	Wednesday 21-Feb-2018	Thursday 22-Feb-2018	Friday 23-Feb-2018
09.00- 09.50	**Independent Learning**	**Lecture** General Approach to the Pregnant Woman Ö. Tanrıöver	**Lecture** Benign Diseases of the Uterus and the Cervix R. Attar	**ICP-CSL** (Clinical breast examination) A. Akalın/ Ö. Tanrıöver **ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar / M. Berber	**Independent Learning**
10.00- 10.50	**Lecture** Menopause C. Fıçıcıoğlu	**Lecture** Malign Diseases of the Uterus and the Cervix M. Aban	**Lecture** Benign Diseases of the Ovary R. Attar	**Group A ICP** **Group B Small Group Study** Scientific Project **Group C1 YH** **Group C2 & D IL**	**Lecture** Urolithiasis-I F. Yencilek
11.00- 11.50	**Lecture** Fertility Control C. Fıçıcıoğlu	**Lecture** Malign Diseases of the Ovary M. Aban	**Lecture** Pathophysiology of Urinary System Diseases I M. Kaçar	**Group C1 IL**	**Lecture** Urolithiasis-II F. Yencilek
12.00- 12.50	**Lecture** Infertility C. Fıçıcıoğlu	**Lecture** Epidemiology, Prevention and Control of Type II Diabetes Mellitus R. E. Sezer	**Lecture** Pathophysiology of Urinary System Diseases II M. Kaçar	**Independent Learning**	**Lecture** Imaging of Urinary System M. Topçuoğlu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Public Health Ethics Lecturer	**Lecture** Phytotherapy-VIII E. Yeşilada	**Lecture** Physical Examination of Newborn Patient M. Berber	**Lecture** Renovascular Pathology I.D. Ekici	**Lecture** Pathology of Male Genital System I I. D. Ekici
15.00- 15.50	**Lecture** Reproductive Ethics Ethics Lecturer	**Lecture** Congenital Infections and Sexually Transmitted Diseases, Genital Infections I M. Sönmezoğlu	**Lecture** Physical Examination of Child Patient M. Berber	**Lecture** Renal Cystic Disease I.D. Ekici	**Lecture** Pathology of Male Genital System II I. D. Ekici
16.00- 16.50	**Lecture** Gene Ethics Ethics Lecturer	**Lecture** Congenital Infections and Sexually Transmitted Diseases, Genital Infections II M. Sönmezoğlu	**Lecture** Nephritic Syndrome Z. Eren	**Independent Learning**	**Lecture** Fluid, Electrolyte I G. Kantarcı
17.00-17.50	**Lecture** The Ethics of Patents on Life Ethics Lecturer	**Lecture** Congenital Infections and Sexually Transmitted Diseases, Genital Infections III M. Sönmezoğlu	**Lecture** Nephrotic Syndrome Z. Eren	**Independent Learning**	**Lecture** Fluid, Electrolyte II G. Kantarcı

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK V / 26 Feb- 2 Mar 2018

<table>
<tr><th></th><th>Monday
26-Feb-2018</th><th>Tuesday
27-Feb-2018</th><th>Wednesday
28-Feb-2018</th><th colspan="4">Thursday
1-Mar-2018</th><th>Friday
2-Mar-2018</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Pathology of Glomerular Diseases I
I. D. Ekici</td><td rowspan="4">OSCE-I EXAM</td><td rowspan="4">OSCE-I EXAM</td><td colspan="2">ICP-CSL
(Physical examination of the newborn and child patient)
F. Bakar/
M. Berber</td><td colspan="2">ICP-CSL
(Clinical breast examination)
A. Akalın/
Ö. Tanrıöver</td><td>Lecture
Acute Kidney Injury
G. Kantarcı</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Pathology of Glomerular Diseases II
I. D. Ekici</td><td rowspan="2">Group A, B2 IL</td><td>Group B1 YH</td><td rowspan="2">Group C
Small Group Study
Scientific Project</td><td rowspan="2">Group D</td><td>Lecture
Acute Kidney Injury
G. Kantarcı</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Pathology of Glomerular Diseases III
I. D. Ekici</td><td>Group B1 IL</td><td>Lecture
Agents Effecting Bone Mineral Homeostasis I
E. Genç</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Relation Between Several Variables
Ç. Altunok</td><td colspan="3">Lecture
Phytotherapy-VII
E. Yeşilada</td><td>Lecture
Agents Effecting Bone Mineral Homeostasis II
E. Genç</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="8">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td>Lecture
Pathology of Tubulointerstitial Disease I
I. D. Ekici</td><td rowspan="4">OSCE-I EXAM</td><td rowspan="4">OSCE-I EXAM</td><td colspan="3">Lecture
Androgens & Anabolic Steroids
E. Genç</td><td>Lecture
Clinical Study of Renal Functions and Urinary Findings
Z. Eren</td></tr>
<tr><td>15.00- 15.50</td><td>Lecture
Pathology of Tubulointerstitial Disease II
I. D. Ekici</td><td colspan="3">Lecture
Upper and Lower Urinary Tract Infections I
A.Ç. Büke</td><td>Lecture
Tubulointerstitial Diseases
Z. Eren</td></tr>
<tr><td>16.00- 16.50</td><td>Independent Learning</td><td colspan="3">Lecture
Upper and Lower Urinary Tract Infections II
A.Ç. Büke</td><td>Lecture
Tubulointerstitial Diseases
Z. Eren</td></tr>
<tr><td>17.00-17.50</td><td>Independent Learning</td><td colspan="3">Independent Learning</td><td>Lecture
Nephritic and Nephrotic Syndrome
D. Torlak</td></tr>
</table>

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK VI / 5-9 Mar 2018

	Monday 5-Mar-2018	Tuesday 6-Mar-2018	Wednesday 7-Mar-2018	Thursday 8-Mar-2018	Friday 9-Mar-2018
09.00- 09.50	**Lecture** Chronic Kidney Disease G. Kantarcı	**Lecture** Pathology of Bladder I. D. Ekici	**Lecture** Congenital Anomalies of The Urinary System S. Sözübir	**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/ M. Berber	**Microbiology Laboratory** (Laboratory Tests-III) Microbiology Instructors: Group A; Group B IL; Group C & D IL
10.00- 10.50	**Lecture** Chronic Kidney Disease G. Kantarcı	**Lecture** Pathology of Urinary System Tumors I. D. Ekici	**Lecture** Acid/ Base Balance I Z. Eren	**Group A, B, C & D2 IL**; **Group D1 YH**	Group A IL; Group B
11.00- 11.50	**Lecture** Urologic Oncology I A. T. Özdemir	**Lecture** Congenital Anomalies of Urinary System I. D. Ekici	**Lecture** Acid/ Base Balance II Z. Eren	**Group 1 IL**	**Microbiology Laboratory** (Laboratory Tests-III) Microbiology Instructors: Group A & B IL; Group C; Group D II
12.00- 12.50	**Lecture** Urologic Oncology II A. T. Özdemir	**Lecture** Approach to the Patient with Urinary Tract Symptoms A. Akalın	**Independent Learning**	**Independent Learning**	Group C II; Group D
12.50 -14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP-CSL** (Clinical breast examination) A. Akalın/ Ö.Tanrıöver	**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/ M. Berber	**ICP-CSL** (Clinical breast examination) A. Akalın/ Ö. Tanrıöver	**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/ M. Berber	**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/ M. Berber	**Lecture** The Kidney Systemic Disease and Inherited Disorders G. Kantarcı
15.00- 15.50	**Group A Small Group Study** Scientific Project; **Group B ICP**; **Group C & D IL**	**Group A1 YH**; **Group A2 & B IL**; **Group C ICP**; **Group B Small Group Study** Scientific Project	**A IL**; **B IL**; **C IL**; **D2 YH**	**A IL**; **B2 YH**; **C IL**; **D IL**	**Lecture** The Kidney Systemic Disease and Inherited Disorders G. Kantarcı
16.00- 16.50		**Group A1 IL**	**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/ M. Berber	**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/ M. Berber	**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**A IL**; **B IL**; **C2 YH**; **D IL**	**A2 YH**; **B IL**; **C IL**; **D IL**	**Independent Learning**

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK VII / 12-16 Mar 2018

<table>
<tr><th></th><th colspan="3">Monday
12-Mar-2018</th><th>Tuesday
13-Mar-2018</th><th>Wednesday
14-Mar-2018</th><th>Thursday
15-Mar-2018</th><th>Friday
16-Mar-2018</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">Pathology Laboratory
(Urinary System)
I. D. Ekici / F. Özkan</td><td>Group A IL</td><td>Group B</td><td>Lecture
Benign Prostatic Hyperplasia-I
H. Koyuncu</td><td rowspan="4">PHYSICIANS’ DAY</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td>Group A</td><td>Group B IL</td><td>Lecture
Benign Prostatic Hyperplasia-II
H. Koyuncu</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Urologic Emergencies
H. Koyuncu</td></tr>
<tr><td>12.00- 12.50</td><td colspan="3">Independent Learning</td><td>Lecture
Transplantation of Kidney
O. Yaprak/ A. Alim</td></tr>
<tr><td>12.50- 14.00</td><td colspan="7">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="3">Pathology Laboratory
(Urinary System)
I. D. Ekici / F. Özkan</td><td>Group A</td><td>Group B IL</td><td>Multidisciplinary
Case Discussion Panel</td><td rowspan="4">PHYSICIANS’ DAY</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td>Group A IL</td><td>Group B</td><td>Multidisciplinary
Case Discussion Panel</td></tr>
<tr><td>16.00- 16.50</td><td>Independent Learning</td></tr>
<tr><td>17.00-17.50</td><td colspan="3">Independent Learning</td><td>Independent Learning</td></tr>
</table>

COMMITTEE IV – ENDOCRINE, REPRODUCTIVE and URINARY SYSTEMS

WEEK VIII / 19 - 23 Mar 2018

<table>
<tr><th></th><th>Monday
19-Mar-2018</th><th>Tuesday
20-Mar-2018</th><th>Wednesday
21-Mar-2018</th><th>Thursday
22-Mar-2018</th><th>Friday
23-Mar-2018</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td></tr>
<tr><td>12.00- 12.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td></tr>
<tr><td>12.50- 14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td>Program Evaluation Session
Committee IV
Coordination Committee Members</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td></tr>
<tr><td>16.00- 16.50</td></tr>
<tr><td>17.00-17.50</td></tr>
</table>

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY

DISTRIBUTION of LECTURE HOURS

March 26, 2018 – May 4, 2018

COMMITTEE DURATION: 6 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	NEUROLOGY	NR	13	1x4=4 (2 Groups)			**17**
	PSYCHIATRY	PCH	12				**12**
	CHILD PSYCHIATRY	C-PCH	3				**3**
	NEUROSURGERY	NRS	16	1x2=2 (2 Groups)			**18**
	PATHOLOGY	PT	11		1x2=2 (2 Groups)		**13**
	PATHOPHYSIOLOGY	PP	2				**2**
	PHARMACOLOGY	PC	17				**17**
	IMMUNOLOGY	IMM	2				**2**
	PEDIATRICS	PED	4				**4**
	PUBLIC HEALTH	PH	4				**4**
	FAMILY MEDICINE	FM	4				**4**
	RADIOLOGY	RAD	1				**1**
	MEDICAL GENETICS	MG	3				**3**
	INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	IDCM	2				**2**
	OPHTALMOLOGY	OPT	3				**3**
	BIOSTATISTICS	BS	4				**4**
	SCIENTIFIC PROJECTS- III	SP	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			2x3=6 (4 Groups)		**6**
TOTAL			**102**	**6**	**8**	**2**	**118**

Coordination Committee

HEAD	Berrin Aktekin, MD, Prof.
SECRETARY	Burcu Örmeci, MD, Assoc. Prof.
MEMBER	Vildan Öztürk, MD, Asst. Prof.
MEMBER	Oğuzhan Zahmacıoğlu, MD, Asst. Prof.
MEMBER	Naz Berfu Akbaş, MD, Assoc. Prof.

COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY
LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
NEUROLOGY	Berrin Aktekin, MD, Prof. Burcu Örmeci, MD, Assoc. Prof. Halide Rengin Bilgen, MD Hakan Şilek, MD
PSYCHIATRY	N. Berfu Akbaş, MD, Assoc. Prof. Okan Taycan, MD, Assoc. Prof.
CHILD PSYCHIATRY	Oğuzhan Zahmacıoğlu, MD, Asst. Prof
NEUROSURGERY	M.Gazi Yaşargil, MD, Prof. Uğur Türe, MD, Prof. Başar Atalay, MD, Prof. Volkan Harput, MD, Asst. Prof. C. Kaan Yaltırık, MD, Asst. Prof.
PATHOLOGY	Ferda Özkan, MD, Prof Işın Doğan Ekici, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Feyza Arıcıoğlu, PhD, Prof.
PEDIATRICS	Mustafa Berber, MD, Asst. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc. Prof. Özlem Tanrıöver, MD, Assoc. Prof.
RADIOLOGY	Başar Sarıkaya, MD, Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof. A. Ç. Büke,MD, Prof.
OPHTALMOLOGY	Vildan Öztürk, MD, Asst. Prof.
BIOSTATISTICS	Çiğdem Altunok, PhD, Asst. Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Güldal İzbırak, MD, Assoc. Prof. Burcu Örmeci, MD, Assoc. Prof. Naz Berfu Akbaş, MD, Assoc. Prof Oğuzhan Zahmacıoğlu, MD Asst. Prof Serdar Özdemir, MD, Asst. Prof.

COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of nervous system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
5. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to nervous system and psychiatry, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on drugs that are effective on nervous system or on clinical conditions related to nervous system and psychiatry ,
8. ***to convey*** necessary knowledge on professional standards, organizational ethics, and ethics of psychiatry***,***
9. ***to convey*** necessary knowledge on common problems in medical research,
10. ***to convey*** knowledge on phytotherapeutic agents,
11. ***to equip with*** basic and advanced clinical skills *(suturing and tying-C7, neuropsychiatric evaluation-C7)* required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of nervous system,
2.0. ***define*** biochemical and psychodynamical basis of behavior,
3.0. ***grade*** physical, psychosocial and cognitive development of child,
4.0. ***explain*** etiopathogenesis of clinical conditions (central and peripheral nervous system disorders, epilepsy, organic brain syndromes, CNS tumors, psychiatric disorders/diseases) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
5.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to to nervous system and psychiatry,
6.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
7.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for

individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,

8.0. at multi-system level and/or related to cardiovascular and respiratory systems system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

8.1. practice of history taking and physical examination (neurological/neuropsychiatric-C7)

8.2. evaluation of emergency case (neurological emergencies-C7)

8.3. approach to healthy individual or patient (neurological symptoms-C7, headache-C7, depression-C7, dementia-C7)

8.4. laboratory tests/examinations

8.5. imaging tests/examinations (conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, brain perfusion scintigraphy-C7, brain PET-C7)

8.6. point of care testing

8.7. making preliminary diagnosis or definitive diagnosis decision

8.8. making non-intervention or intervention decision

8.9. practicing non-intervention or intervention

8.10. referral/transport of healthy individual or patient

9.0. ***explain*** pharmacology of drugs (parkinsonism and other movement disorders, antiepileptics, CNS stimulants and hallusinogenic drugs, sedative/hypnotic drugs, opioid analgesics and antagonists, general/local anesthetics, antipsychotic drugs, bipolar disease and lithium, antidepressant drugs, alcohols, drug dependence and abuse) that are effective on nervous system or on clinical conditions related to nervous system and psychiatry,

10.0.***describe*** professional standards, organizational ethics, and ethics in psychiatry,

11.0.***describe*** phytotherapeutic agents (“HMPs, Nutraceutics”),

12.0. ***list*** common problems in medical research,

13.0. ***perform*** basic clinical skills, practiced on phantom models (suturing and tying-C7), and advanced clinical skills, practiced on simulated/standardized patients (neuropsychiatric evaluation-C7), required at primary health care service.

COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY
COMMITTEE ASSESSMENT MATRIX

PHASE III
COURSE: MD 302 INTRODUCTION TO CLINICAL SCIENCES
COURSE COMPONENT: COMMITTEE V - NERVOUS SYSTEM and PSYCHIATRY

QUESTION DISTRIBUTION TABLE

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS (MCQ)			
			CE	FE	IE	Total
9.0.	PC	E. Genç	14	5	5	**24**
9.0.		F. Arıcıoğlu				
1.0., 4.0.-8.0.	NRS	M. G. Yaşargil	13	5	5	**23**
1.0., 4.0.-8.0.		B. Atalay				
1.0., 4.0.-8.0.		U. Türe				
1.0., 4.0.-8.0.	NR	B. Aktekin	11	4	4	**19**
1.0., 4.0.-8.0.		B. Örmeci				
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	B. Akbas	10	4	4	**18**
1.0., 4.0., 7.0.	PT	F. Özkan	10	3	3	**16**
1.0., 4.0., 7.0.		I.D. Ekici				
1.0., 3.0.-8.0.	PED	M. Berber	4	1	1	**6**
	IMM	G. Y. Demirel	2	1	1	**4**
5.0., 6.0.	PH	R.E. Sezer	4	1	1	**6**
8.3.	FM	G. İzbırak	4	1	1	**6**
8.3.						
8.3.		Ö. Tanrıöver				
12.0.	BS	Ç. Altunok	4	1	1	**6**
2.0.	MG	A. Ç. Kuşkucu	3	1	1	**5**
2.0.-8.0., 10.0.	C-PCH	O. Zahmacıoglu	3	1	1	**5**
1.0., 4.0.-8.0.	OPT	V. Öztürk	3	1	1	**5**
4.0., 7.0.	PP	M. Kaçar	2	1	1	**4**
4.0.-7.0, 8.4.	IDCM	M. Sönmezoğlu	2	1	1	**4**
4.0.-8.0.		A. Ç. Büke				
8.5.	RAD	A. Sarsılmaz	1	0	0	**1**
TOTAL			**90**	**31**	**31**	**152**

LEARNING OBJECTIVE	FACULTY DEPARTMENT	LECTURER/ INSTRUCTOR	NUMBER OF QUESTIONS (EMQ)			
			CE	FE	IE	Total
1.0., 4.0.-8.0.	NR	B. Ormeci	1	-	-	**1**
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	B. Akbaş	1	-	-	**1**
	PC	E. Genç	1			**1**
1.0., 4.0.-8.0.	NRS	B. Atalay	2			**2**
TOTAL			**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**
*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.
MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
pts: Points
****31** out of 200 FE and ICE MCQs will be from Committee V (Each question is of worth 0.5 points).

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY
WEEK I / 26-30 Mar 2018

	Monday 26-Mar-2018	Tuesday 27-Mar-2018	Wednesday 28-Mar-2018	Thursday 29-Mar-2018	Friday 30-Mar-2018
09.00- 09.50	**Independent Learning**	**Lecture** Pathology of Myelin & Neuronal Storage Diseases I I. D. Ekici	**Lecture** Neurodegenerative Disorders M. Berber	**Independent Learning**	**Lecture** Neurodegenerative Disorders I F. Özkan
10.00- 10.50	**Lecture** Signs and Symptoms in Neurology B. Aktekin	**Lecture** Pathology of Myelin & Neuronal Storage Diseases II I. D. Ekici	**Lecture** Cerebral Lobes and their Disorders B. Örmeci		**Lecture** Neurodegenerative Disorders II F. Özkan
11.00- 11.50	**Lecture** Cranial Nerves I R. Bilgen	**Lecture** Developmental Disorders of CNS I. D. Ekici	**Lecture** Cerebrovascular Disease H. Şilek		**Lecture** Headache in Neurologic Patient H. Şilek
12.00- 12.50	**Lecture** Cranial Nerves II R. Bilgen	**Lecture** Introduction to Central Nervous System Pharmacology E. Genç	**Lecture** Degenerative Diseases of the Spine and the Spinal Cord I B. Atalay		**Lecture** Neurological Emergencies R. Bilgen
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pathophysiology of Nervous System Diseases I M. Kaçar	**Lecture** Demyelinating Disorders I R. Bilgen	**Lecture** Degenerative Diseases of the Spine and the Spinal Cord II B. Atalay	**Lecture** Pharmacological Approach to Parkinsonism & Other Movement Disorders I E. Genç	**Lecture** Antimigraine Drugs Pharmacology Lecturer
15.00- 15.50	**Lecture** Pathophysiology of Nervous System Diseases I M. Kaçar	**Lecture** Demyelinating Disorders II R. Bilgen	**Lecture** Dementia B. Örmeci	**Lecture** Pharmacological Approach to Parkinsonism & Other Movement Disorders II E. Genç	**Lecture** Antiepileptics E. Genç
16.00- 16.50	**Independent Learning**	**Independent Learning**	**Lecture** Extrapyramidal System Disorders B. Örmeci	**Independent Learning**	**Lecture** Antipsychotic Drugs F. Arıcıoğlu
17.00-17.50	**Independent Learning**		**Independent Learning**	**Independent Learning**	**Lecture** Bipolar Disease & Lithium F. Arıcıoğlu

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY
WEEK II / 02-06 Apr 2018

	Monday 2-Apr-2018	Tuesday 3-Apr-2018	Wednesday 4-Apr-2018	Thursday 5-Apr-2018	Friday 6-Apr-2018
09.00- 09.50	**Lecture** Clinical Presentation, Anatomic Concepts and Diagnosis in a Neurosurgical Patient C. Kaan Yaltırık	**Lecture** Public Health and Aging I R. E. Sezer	**Neurology Clinical Training** B. Aktekin	**Neurology Clinical Training** B. Örmeci	**Lecture** Peripheral Nerve Disorders H. Şilek
10.00- 10.50	**Lecture** Pediatric Neurosurgery C. Kaan Yaltırık	**Lecture** Public Health and Aging II R. E. Sezer	**Group A** / **Group B** / **Group C IL** / **Group D IL**	**Group A IL** / **Group B IL** / **Group C** / **Group D**	**Lecture** Epilepsy B. Aktekin
11.00- 11.50	**Lecture** Hydrocephalus C. Kaan Yaltırık	**Lecture** Paralytic Strabismus and Nistagmus V. Öztürk			**Lecture** Cranial Trauma & İntracranial Hemorrhage I F. Özkan
12.00- 12.50	**Lecture** Conventional Neuroradiological Examinations B. Sarıkaya	**Independent Learning**			**Lecture** Cranial Trauma & İntracranial Hemorrhage II F. Özkan
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Neurosurgical Infections C. Kaan Yaltırık	**Lecture** Surgical Neuroanatomy U. Türe	**Lecture** Design of Survival Studies Ç. Altunok	**Lecture** Diseases of Optic Nerves and Visual Fields V. Öztürk	**Lecture** Acute and Chronic Meningitis, Encephalitis I M. Sönmezoğlu
15.00- 15.50	**Lecture** Spinal Cord Compression and Spinal Tumors B. Atalay	**Lecture** Cerebrovascular Diseases in Neurosurgery I U. Türe	**Lecture** Neuroimmunological Disorders G. Yanıkkaya Demirel	**Lecture** Pupilla V. Öztürk	**Lecture** Culture, Health and Illness R. E. Sezer
16.00- 16.50	**Lecture** Peripheral Nerve Compression Sydromes B. Atalay	**Lecture** Cerebrovascular Diseases in Neurosurgery II U. Türe	**Lecture** Neuroimmunological Disorders G. Yanıkkaya Demirel	**Independent Learning**	**Lecture** Behavioral Determinants of Health and Disease R. E. Sezer
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY
WEEK III / 26-30 Mar 2018

	Monday 9-Apr-2018	Tuesday 10-Apr-2018	Wednesday 11-Apr-2018	Thursday 12-Apr-2018	Friday 13-Apr-2018
09.00- 09.50	**Lecture** Tumors of CNS I **I. D. Ekici**	**Independent Learning**	**Neurosurgery Clinical Training** V. Harput	**Pathology Laboratory** (Nervous System) I. D. Ekici / F. Özkan	**Neurosurgery Clinical Training** C. Kaan Yaltırık
10.00- 10.50	**Lecture** Tumors of CNS II **I. D. Ekici**	**Lecture** Functional Neurosurgery V. Harput	**Group A** / **Group B** / **Group C IL** / **Group D IL**	**Group A IL** / **Group B**	**Group A IL** / **Group B IL** / **Group C** / **Group D**
11.00- 11.50	**Lecture** Intracranial Tumors II M. Gazi Yaşargil	**Lecture** Spinal Trauma in Neurosurgery V. Harput	**Lecture** Genetic Etiology of Mental Retardation I A. Ç. Kuşkucu	**Group A** / **Group B IL**	**Lecture** Analysis of Survival Studies I Ç. Altunok
12.00- 12.50	**Lecture** Intracranial Tumors I M. Gazi Yaşargil	**Lecture** Cranial Trauma in Neurosurgery V. Harput	**Lecture** Genetic Etiology of Mental Retardation II A. Ç. Kuşkucu		**Lecture** Analysis of Survival Studies II Ç. Altunok
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Cerebral Malformations M. Berber	**Lecture** Acute and Chronic Meningitis, Encephalitis II M. Sönmezoğlu	**Lecture** Opioid Analgesics & Antagonists I E. Genç	**Lecture** Introduction to Psychiatry O. Taycan	**Lecture** Local Anesthetics E. Genç
15.00- 15.50	**Lecture** Mental and Motor Development M. Berber	**Lecture** Infectious Diseases of CNS I I.D. Ekici	**Lecture** Opioid Analgesics & Antagonists II E. Genç	**Lecture** Psychiatric Interview, History O. Taycan	**Lecture** General Anesthetics E. Genç
16.00- 16.50	**Lecture** Infectious Disease of the Nervous System M. Berber	**Lecture** Infectious Diseases of CNS II I.D. Ekici	**Lecture** Psychiatric Epidemiology and Classification N.B. Akbaş	**Lecture** Signs and Symptoms in Psychiatry O. Taycan	**Independent Learning Lecture** Genetic Aspects of Psychiatric Disorders A. Ç. Kuşkucu
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY
WEEK IV / 2-6 Apr 2018

	Monday 16-Apr-2018	Tuesday 17-Apr-2018	Wednesday 18-Apr-2018	Thursday 19-Apr-2018	Friday 20-Apr-2018
09.00- 09.50	**Lecture** Neuroscience I N.B. Akbaş	**Lecture** Schizophrenia Spectrum and Other Psychotic Disorders I O. Taycan	**ICP-CSL** (General physical examination) G. İzbırak/ S. Özdemir	**ICP-CSL** (Neurological examination & psychiatric examination) N. B. Akbaş/ O. Zahmacıoğlu/ B. Örmeci	**Lecture** Introduction to Child and Adolescent Psychiatry O. Zahmacıoğlu
10.00- 10.50	**Lecture** Neuroscience II N.B. Akbaş	**Lecture** Schizophrenia Spectrum and Other Psychotic Disorders II O. Taycan	**Group A ICP** / **Group B IL** / **Group C IL** / **Group D IL**	**Group A** **Small Group Study** Scientific Project / **Group B ICP** / **Group C IL** / **Group D IL**	**Lecture** Common Childhood Psychiatric Problems O. Zahmacıoğlu
11.00- 11.50	**Lecture** Developmental Psychopathology: Risk and Protective Factors in Mental Development O. Taycan	**Lecture** Drug Dependence & Abuse E. Genç			**Lecture** Mental Development in Childhood and Adolescence O. Zahmacıoğlu
12.00- 12.50	**Lecture** Approach to Smoking Patient in Primary Care Ö. Tanrıöver	**Lecture** The Alcohols E. Genç	**Independent Learning**	**Independent Learning**	**Lecture** Sedative / Hypnotic Drugs I E. Genç
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Antidepressant Drugs E. Genç	**Lecture** Mood Disorders I B. Akbaş	**ICP-CSL** (Neurological examination & psychiatric examination) N. B. Akbaş/ O. Zahmacıoğlu/ B. Örmeci	**ICP-CSL** (General physical examination) G. İzbırak/ S. Özdemir	**Lecture** Sedative / Hypnotic Drugs II E. Genç
15.00- 15.50	**Independent Learning**	**Lecture** Mood Disorders II B. Akbaş	**Group A ICP** / **Group B** **Small Group Study** Scientific Project / **Group C IL** / **Group D IL**	**Group A IL** / **Group B ICP** / **Group C IL** / **Group D IL**	**Lecture** Depression in Primary Care G. İzbırak
16.00- 16.50	**Independent Learning**	**Lecture** Anxiety Disorders: An Introduction B. Akbaş			**Lecture** General Physical Exam G. İzbırak
17.00-17.50	**Independent Learning**	**Lecture** CNS Stimulants and Hallusinogenic Drugs E. Genç	**Lecture** Approach to the Patient with Dementia in Primary Care G. İzbırak	**Independent Learning**	**Independent Learning**

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY
WEEK V / 9-13 Apr 2018

<table>
<tr><th></th><th>Monday
23-Apr-2018</th><th>Tuesday
24-Apr-2018</th><th>Wednesday
25-Apr-2018</th><th>Thursday
26-Apr-2018</th><th>Friday
27-Apr-2018</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">NATIONAL HOLIDAY</td><td colspan="4">ICP-CSL
(Neurological examination & psychiatric examination)
N.B. Akbaş/ O. Zahmacıoğlu/ B. Örmeci/</td><td colspan="4">ICP-CSL
(neurological examination & psychiatric examination)
N.B. Akbaş/ O. Zahmacıoğlu/ B. Örmeci/</td><td>Multidisciplinary Case Discussion Panel</td><td rowspan="3">Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td>Group A IL</td><td>Group B IL</td><td>Group D ICP</td><td>Group C Small Group Study Scientific Project</td><td>Group A IL</td><td>Group B IL</td><td>Group D Small Group Study Scientific Project</td><td>Group C ICP</td><td>Multidisciplinary Case Discussion Panel</td></tr>
<tr><td>11.00- 11.50</td><td colspan="8">Independent Learning</td></tr>
<tr><td>12.00- 12.50</td><td colspan="9"></td></tr>
<tr><td>12.50 – 14.00</td><td colspan="9">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="4">NATIONAL HOLIDAY</td><td colspan="4">ICP-CSL
(General physical examination)
G. İzbırak/ S. Özdemir</td><td colspan="4">ICP-CSL
(General physical examination)
G. İzbırak/ S. Özdemir</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td>Group A IL</td><td>Group B IL</td><td>Group D ICP</td><td>Group C IL</td><td>Group A IL</td><td>Group B IL</td><td>Group D IL</td><td>Group C ICP</td></tr>
<tr><td>16.00- 16.50</td><td colspan="9"></td></tr>
<tr><td>17.00-17.50</td><td colspan="4">Independent Learning</td><td colspan="4">Independent Learning</td></tr>
</table>

COMMITTEE V - NERVOUS SYSTEM AND PYSCHIATRY
WEEK VI / 16-20 Apr 2018

	Monday 30-Apr-2018	Tuesday 1-May-2018	Wednesday 2-May-2018	Thursday 3-May-2018	Friday 4-May-2018
09.00- 09.50	Independent Learning	LABOUR'S DAY	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	LABOUR'S DAY	Independent Learning	Independent Learning	**Program Evaluation Session** Committee V Coordination Committee Members
15.00- 15.50					Independent Learning
16.00- 16.50					
17.00-17.50					

COMMITTEE VI - MUSCULOSKELETAL SYSTEM

DISTRIBUTION of LECTURE HOURS

May 7, 2018 – Jun 1, 2018

COMMITTEE DURATION: 4 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	ORTHOPAEDICS & TRAUMATOLOGY	ORT	22				**22**
	PHYSICAL MEDICINE AND REHABILITATION	PTR	2				**2**
	RHEUMATOLOGY	RHE	8				**8**
	PATHOLOGY	PT	11		1x2=2 (4 Groups)		**13**
	PATHOPHYSIOLOGY	PP	2				**2**
	PHARMACOLOGY	PC	5				**5**
	IMMUNOLOGY	IMM	2				**2**
	PUBLIC HEALTH	PH	4				**4**
	FAMILY MEDICINE	FM	1				**1**
	MEDICAL GENETICS	MG	2				**2**
	RADIOLOGY	RAD	1				**1**
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	2				**2**
	EMERGENCY MEDICINE	EM	1				**1**
	BIOSTATISTICS	BS	3				**3**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			1x3=3 (4 Groups)		**3**
TOTAL			**66**	**0**	**5**	**2**	**73**

Coordination Committee

HEAD	Uğur Şaylı, MD, Prof.
SECRETARY	Müge Bıçakçıgil, MD, Assoc. Prof
MEMBER	Melih Güven, MD, Assoc. Prof
MEMBER	Ece Aydoğ, MD, Prof.
MEMBER	Serdar Özdemir, MD, Asst. Prof.

COMMITTEE VI - MUSCULOSKELETAL SYSTEM

LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**FACULTY**
ORTHOPAEDICS & TRAUMATOLOGY	Faik Altıntaş, MD, Prof. Uğur Şaylı, MD, Prof. Turhan Özler, MD, Assoc Prof. Melih Güven, MD, Assoc.Prof. Çağatay Uluçay, MD, Assoc. Prof. Budak Akman, MD. Onur Kocadal, MD.
PHYSICAL MEDICINE AND REHABILITATION	Ece Aydoğ, MD, Prof. Feyza Arıcıoğlu, PhD, Prof.
RHEUMATOLOGY	Müge Bıçakçıgil, MD, Assoc. Prof
PATHOLOGY	Ferda Özkan, MD, Prof Işın Doğan Ekici, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof.
IMMUNOLOGY	Gülderen Yanıkkaya Demirel, MD, PhD, Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Asst. Prof
FAMILY MEDICINE	Özlem Tanrıöver, MD, Assoc. Prof
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
RADIOLOGY	Neslihan Taşdelen, MD, Assoc. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Hakan Ertin, MD, Assoc. Prof. Rainer Brömer, PhD, Assoc. Prof.
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD, Assoc.Prof
BIOSTATISTICS	Çiğdem Altunok, PhD, Asst. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Çağatay Uluçay, MD, Assoc. Prof. Turhan Özler, MD, Assoc. Prof. Budak Akman, MD Onur Kocadal, MD.

COMMITTEE VI - MUSCULOSKELETAL SYSTEM

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of musculoskeletal system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,
5. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to musculoskeletal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on pharmacology of drugs that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,
8. ***to convey*** necessary knowledge on ethics in biomedical research,
9. ***to convey*** necessary knowledge on clinical research methods and searching medical literature,
10. ***to convey*** necessary knowledge on phytotherapeutic agents,
11. ***to equip with*** basic and advanced clinical skills (peripheral venous catheter insertion-C8, physical examination of musculoskeletal system-C8) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of musculoskeletal system,

2.0. ***explain*** etiopathogenesis of clinical conditions (congenital, traumatic, metabolic, degenerative, onocological conditions of bone, rheumotological disorders, disaeses/disorders of connective tissue, vascular diseases, pathological posture, pain) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,

3.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,

4.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,

5.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for

individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,

6.0. at multi-system level and/or related to cardiovascular and respiratory systems system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

6.1. practice of history taking and physical examination (musculoskeletal-C8)
6.2. evaluation of emergency case (trauma-C8)
6.3. approach to healthy individual or patient (musculoskeletal dysfunction-C8)
6.4. laboratory tests/examinations (monitarization of drug therapy-C8)
6.5. imaging tests/examinations (radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8, bone scintigraphy-C8)
6.6. point of care testing
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient

7.0. ***explain*** pharmacology of drugs (non-opioid analgesics, skeletal muscle relaxants, disease modifying antirheumatic drugs) that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,

8.0. ***explain*** effects of phytotherapeutic agents on musculoskeletal system or on clinical conditions related to musculoskeletal system,

9.0. ***list*** ethical principles in biomedical research,

10.0.***explain*** use of biostatistics in clinical research and for evidence search in medical literature,

11.0. ***perform*** basic clinical skills, practiced on phantom models (peripheral venous catheter insertion-C8), and advanced clinical skills, practiced on simulated/standardized patients (physical examination of musculoskeletal system-C8), required at primary health care service.

COMMITTEE VI - MUSCULOSKELETAL SYSTEM

COMMITTEE ASSESSMENT MATRIX

COURSE: MD 302 INTRODUCTION TO CLINICAL SCIENCES **COURSE COMPONENT:** COMMITTEE VI - MUSCULOSKELETAL SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/ INSTRUCTOR**	**NUMBER OF QUESTIONS (MCQ)**			
			CE	**FE**	**IE**	**Total**
1.0.-6.0.	ORT	F. Altıntaş	29	6	6	**41**
1.0.-6.0.		T. Özler				
1.0.-6.0.		Ç. Uluçay				
1.0.-6.0.		M. Güven				
1.0., 2.0., 5.0.	PT	F. Özkan	16	3	3	**22**
		I. D. Ekici				
		A. S. Çöloğlu				
1.0.-6.0.	RHE	M. Bıçakçıgil	11	2	2	**15**
7.0.	PC	E. Genç	7	2	2	**11**
7.0.		F. Arıcıoğlu				
3.0., 4.0.	PH	R.E. Sezer	5	1	1	**7**
3.0., 4.0.		H.A.Taşyıkan				
1.0.-6.0.	PTR	E. Aydoğ	3	1	1	**5**
	IMM	G. Yanıkkaya Demirel	3	1	1	**5**
10.0.	BS	Ç. Altunok	4	1	1	**6**
1.0., 2.0., 5.0.	PP	M. Kaçar	3	1	1	**5**
2.0.	MG	A. Ç. Kuşkucu	3	1	1	**5**
6.3.	FM	Ö. Tanrıöver	1	1	1	**3**
6.3.						
9.0.	BED	H. Ertin / R. Brömer	3	1	1	**5**
6.2.	EM	S. Sarıkaya	1	0	0	**1**
6.5.	RAD	N. Taşdelen	1	0	0	**1**
TOTAL			**90**	**21**	**21**	**132**
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/INSTRUCTOR**	**NUMBER OF QUESTIONS (EMQ)**			
			CE	**FE**	**IE**	**Total**
1.0.-6.0.	RHE	M. Bıçakçıgil	1	-	-	1
1.0.-6.0.	ORT	M. Güven	2	-	-	2
1.0.-6.0.	PTR	E. Aydoğ	2			2
TOTAL			**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**
*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.
MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
pts: Points
****21** out of 200 FE and ICE MCQs will be from Committee VI (Each question is of worth **0.5** pts).

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK I / 7-11 May 2018

	Monday 7-May-2018	Tuesday 8-May-2018	Wednesday 9-May-2018	Thursday 10-May-2018	Friday 11-May-2018
09.00- 09.50	**Lecture** Introduction to Musculoskeletal System F. Altıntaş	**Lecture** Degenerative Joint Disease F. Özkan	**Lecture** Public Health and Physical Activity I R. E. Sezer	**ICP-CSL** (Physical examination of the musculoskeletal system) T. Özler/ B. Akman	**Lecture** Osteoporosis and Osteoarthritis Treatment, Rehabilitation E. Aydoğ
10.00- 10.50	**Lecture** Degenerative Osteoarthrosis F. Altıntaş	**Lecture** Tumors of Soft Tissues I F. Özkan	**Lecture** Public Health and Physical Activity II R. E. Sezer	**Group A ICP** / **Group B Small Group Study** Scientific Project / **Group C IL** / **Group D IL**	**Lecture** Soft Tissue Pain E. Aydoğ
11.00- 11.50	**Lecture** Pathophysiology of Musculoskeletal System Disorders I M. Kaçar	**Lecture** Tumors of Soft Tissues II F. Özkan	**Lecture** Spondylarthropaties M. Bıçakçıgil		**Lecture** Bone and Joint İnfections I.D. Ekici
12.00- 12.50	**Lecture** Pathophysiology of Musculoskeletal System Disorders II M. Kaçar	**Lecture** Imaging of Musculoskeletal System N. Taşdelen	**Lecture** Inflammatory Polyarthritis & Rheumatoid Arthritis M. Bıçakçıgil	**Independent learning**	**Lecture** Myopathies I.D. Ekici
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Congenital & Metabolic Diseases of Bone I I.D. Ekici	**Lecture** Vasculitis I F. Özkan	**Lecture** Epidemiology, Prevention and Control of Occupational Diseases and Injuries I H.A. Taşyıkan	**Lecture** Osteomyelitis and Septic Artritis B. Akman	**Independent Learning**
15.00- 15.50	**Lecture** Congenital & Metabolic Diseases of Bone II I.D. Ekici	**Lecture** Vasculitis II F. Özkan	**Lecture** Epidemiology, Prevention and Control of Occupational Diseases and Injuries II H.A. Taşyıkan	**Lecture** Neuromuscular Disease O. Kocadal	**Independent Learning**
16.00- 16.50	**Independent Learning**	**Lecture** Transhumanisms and Ethics Lecturer	**Independent Learning**	**Independent Learning**	**Independent Learning**
17.00-17.50	**Independent Learning**	**Lecture** Ethics of the Future/Future of Ethics Lecturer	**Independent Learning**	**Independent Learning**	**Independent Learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK II / 14-18 May 2018

	Monday 14-May-2018	Tuesday 15-May-2018	Wednesday 16-May-2018	Thursday 17-May-2018	Friday 18-May-2018
09.00- 09.50	**Independent Learning**	**Lecture** Connective Tissue Disorders I M. Bıçakçıgil	**Lecture** Foot Deformities U. Şaylı	**ICP-CSL** **(**Physical examination of the musculoskeletal system) T. Özler / Ç. Uluçay / O. Kocadal	**Lecture** Lower Extremity Trauma Ç. Uluçay
10.00- 10.50	**Lecture** Miscellanous Rheumatological Disorders I M. Bıçakçıgil	**Lecture** Connective Tissue Disorders II M. Bıçakçıgil	**Lecture** Principles of Fracture Healing U. Şaylı	**Group A** **Small Group Study** Scientific Project **Group B** **ICP** **Group C IL** **Group D IL**	**Lecture** Traumatic Dislocations Ç. Uluçay
11.00- 11.50	**Lecture** Miscellanous Rheumatological Disorders II M. Bıçakçıgil	**Lecture** Management of the Trauma Patient T. Özler	**Lecture** Sport Injuries of Lower Extremity T. Özler		**Lecture** Spinal Trauma G. Meriç
12.00- 12.50	**Lecture** Miscellanous Rheumatological Disorders III M. Bıçakçıgil	**Lecture** Upper Extremity Trauma T. Özler	**Lecture** Sport Injuries of Upper Extremity T. Özler	**Independent Learning**	**Lecture** Skeletal Dysplasias A. Ç. Kuşkucu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Neck, Shoulder and Wrist Pain Ö. Ortancıl	**Lecture** Fractures of Children M. Güven	**ICP-CSL** (Physical examination of the musculoskeletal system) T. Özler/ Ç. Uluçay/ O. Kocadal	**ICP-CSL** (Physical examination of the musculoskeletal system) T. Özler/ B. Akman	**Independent Learning**
15.00- 15.50	**Lecture** Low Back, Hip and Ankle Pain Ö. Ortancıl	**Lecture** Development Dysplasia of the Hip M. Güven	**Group A IL** **Group B IL** **Group C** **Small Group Study** Scientific Project **Group D** **ICP**	**Group A IL** **Group B IL** **Group C** **ICP** **Group D** **Small Group Study** Scientific Project	**Lecture** Initial Approach to Trauma Patient S. Sarıkaya
16.00- 16.50	**Independent Learning**	**Lecture** Developmental Disorders of the Skeleton O. Kocadal			**Independent Learning** ***SPRING FEST***
17.00-17.50	**Independent Learning**	**Independent Learning** ***SPRING FEST***	**Independent Learning** ***SPRING FEST***	**Independent Learning** ***SPRING FEST***	**Independent Learning** ***SPRING FEST***

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK III / 21-25 May 2018

	Monday 21-May-2018	Tuesday 22-May-2018	Wednesday 23-May-2018	Thursday 24-May-2018	Friday 25-May-2018
09.00- 09.50	**Lecture** Upper Extremity Disorders Ç. Uluçay	**Lecture** Disease Modifying Antirheumatic Drugs F. Arıcıoğlu	**Lecture** Osteoporosis B. Akman	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Lecture** Lower Extremity Disorders Ç. Uluçay	**Lecture** Pharmacology Case Studies F. Arıcıoğlu	**Lecture** Microsurgery and Replantation B. Akman		
11.00- 11.50	**Lecture** Benign Tumors of Bone M. Güven	**Lecture** Skeletal Muscle Relaxants E. Genç	**Lecture** Some Common Problems in Medical Research Ç. Altunok		
12.00- 12.50	**Lecture** Malignant Tumors of Bone M. Güven	**Lecture** Approach to the Patient with Backpain in Primary Care Ö. Tanrıöver	**Lecture** Power Analysis and Sample Size Calculation I Ç. Altunok		
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Nonsteroidal Antiinflammatory Drugs I E. Genç	**Lecture** Bone Tumors I I.D. Ekici	**Lecture** Power analysis and sample size calculation II Ç. Altunok	**Multidisciplinary Case Discussion Panel**	**Independent Learning**
15.00- 15.50	**Lecture** Nonsteroidal Antiinflammatory Drugs II E. Genç	**Lecture** Bone Tumors II I.D. Ekici	**Lecture** Immune Mechanisms of Musculoskeletal Disorders G. Yanıkkaya Demirel	**Multidisciplinary Case Discussion Panel**	
16.00- 16.50	**Lecture** Vasculitis I M. Bıçakçıgil	**Pathology Laboratory** (Musculoskeletal System) I. D. Ekici/F. Özkan Group A Group B IL	**Lecture** Immune Mechanisms of Musculoskeletal Disorders G. Yanıkkaya Demirel	**Independent Learning**	
17.00-17.50	**Lecture** Vasculitis II M. Bıçakçıgil	Group A IL Group B	**Lecture** Muscular Dystrophies A. Ç.Kuşkucu		

COMMITTEE VI - MUSCULOSKELETAL SYSTEM
WEEK IV / 28 May- 1 Jun 2018

<table>
<tr><th></th><th>Monday
28-May-2018</th><th>Tuesday
29-May-2018</th><th>Wednesday
30-May-2018</th><th>Thursday
31-May-2018</th><th>Friday
1-Jun-2018</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td></tr>
<tr><td>12.00- 12.50</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td>Program Evaluation Session
Committee VI
Coordination Committee
Members</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="3">Independent Learning</td></tr>
<tr><td>16.00- 16.50</td></tr>
<tr><td>17.00-17.50</td></tr>
</table>

STUDENT COUNSELING

Student counseling is a structured development process established between the student and the consultant that aims to maximize student success by focusing the student to her/his target. Although the major component of this relationship is the student, the faculties also take part by bringing the requirements of this interaction to their systems. The targeted outcomes of the consultant-student interaction are success in the exams, success in the program, and preparation for the professional life.
The aim of counseling is to help students to solve their problems, to give professional guidance, to provide coaching, to contribute to adopting the habit of lifelong learning, to provide information about the University and Faculty, to follow their success and failure and to help them select courses.
The consultants selected among Basic Medical Sciences instructors for the first three years transfer the students to Clinical Sciences instructors for the following three years.

The topics that will be addressed by the consultants are as follows:

a. Inform students about the university, faculty and surrounding facilities
b. Inform students about the courses and help them select courses
c. Inform students about the education and assessment regulations
d. Follow students attendance to lectures and success
e. In case of failure, investigate the causes and cooperate with the students to overcome them
f. Help students in career planning
g. Contribute to students adapting the habit of lifelong learning
h. Guide students to counseling services of the university
i. Set a role model as long as the professional susceptibility, professional guidance, intellectual responsibility, interaction with peers, ethics, professional values are concerned
j. Contribute to cultivation of professional and intellectual development in a rapidly changing world
k. Inform the coordinator when there are unsolved problems of the students

Consultant-student relationship is a dynamic and mutual process carried out within the campus and the hospital. It is recommended that the consultant and the student meet at least twice during a semester.

The expectations from the student are as follows:

a) Contribute to improvement of satisfaction level in the problem areas
b) Report the social and economic conditions that require consultant's help
c) Specify expectations from the education and the department from which this training is taken
d) Give feedback on the counseling services regarding their satisfaction level

Student counsellors will be appointed after finalization of the class list and will be announced to the students.
After the announcement of the counsellors on the information board, each student is expected to contact his/her counsellor until the end of the current committee.

LIST OF STUDENT COUNSELING - PHASE III

	NO	NAME	SURNAME	ACADEMIC ADVISOR
1	20140800012	DAMLA	ACAR	PROF. DR. İNCİ ÖZDEN
2	20150800101	DUYGU	AÇIKTEPE	YRD. DOÇ. DR. HALE ARIK TAŞYIKAN
3	20140800016	CANSELİ	AÇIL	YRD. DOÇ. DR. ÇİĞDEM ALTUNOK
4	20170800112	SALİME NUR	AFŞAR	PROF. DR. İNCİ ÖZDEN
5	20140800002	BERFİN ECE	AKBULUT	YRD. DOÇ. DR. HALE ARIK TAŞYIKAN
6	20140800054	CEYDA	AKDİ	YRD. DOÇ. DR. HALE ARIK TAŞYIKAN
7	20150800032	UMUT DENİZ	AKDAĞ	PROF. DR. TURGAY İSBİR
8	20150800078	İLAYDA	AKPINAR	PROF. DR. TURGAY İSBİR
9	20150800013	DEFNE	AKSOY	PROF. DR. TURGAY İSBİR
10	20140800043	DİLAN	ASLAN	YRD. DOÇ. DR. AYLİN YABA UÇAR
11	20140800078	EZGİ	ATEŞ	YRD. DOÇ. DR. AYLİN YABA UÇAR
12	20140800025	GÖZDE	ATMACA	YRD. DOÇ. DR. AYLİN YABA UÇAR
13	20150800049	YASİN FIRAT	AYDOĞAN	PROF. DR. ECE GENÇ
14	20150800029	BERKAY	AYGÜN	PROF. DR. ECE GENÇ
15	20150800091	İBRAHİM	AZİMLİ	PROF. DR. ECE GENÇ
16	20150800051	MEHMET DENİZ	BAKAN	PROF. DR. İNCİ ÖZDEN
17	20150800105	BEGÜM	BALCI	YRD. DOÇ. DR. HALE ARIK TAŞYIKAN
18	20140800044	ILGIN	BARUT	YRD. DOÇ. DR. ÇİĞDEM ALTUNOK
19	20140800062	MERVE SELİN	BAYKAN	YRD. DOÇ. DR. ÇİĞDEM ALTUNOK
20	20150800090	CEMAL BARTU	BEKTAŞ	PROF. DR. TURGAY İSBİR
21	20140800006	ECE	BIÇAKÇI	PROF. DR. İNCİ ÖZDEN
22	20150800015	BİRSU	BİLGİNOĞLU	PROF. DR. TURGAY İSBİR
23	20150800040	BUĞRA BERKAN	BİNGÖL	PROF. DR. TURGAY İSBİR
24	20150800076	NİLSU	BOYACIOĞLU	YRD. DOÇ. DR. BİLGE GÜVENÇ TUNA
25	20140800021	METE	CEVAHİR	YRD. DOÇ. DR. BİLGE GÜVENÇ TUNA
26	20150800084	ÇAĞKAN	CEYRAN	YRD. DOÇ. DR. BİLGE GÜVENÇ TUNA
27	20150800077	İREM	COŞKUN	YRD. DOÇ. DR. HALE ARIK TAŞYIKAN
28	20150800052	MUSTAFA	ÇAĞAN	YRD. DOÇ. DR. HALE ARIK TAŞYIKAN
29	20140800048	ŞEYMA	ÇALIK	YRD. DOÇ. DR. HALE ARIK TAŞYIKAN
30	20150800023	SARPER	ÇALIŞKAN	YRD. DOÇ. DR. AYLİN YABA UÇAR
31	20150800002	ÖZGÜN RÜZGAR	ÇATAL	YRD. DOÇ. DR. AYLİN YABA UÇAR
32	20150800044	YİĞİTCAN	ÇELİK	YRD. DOÇ. DR. AYLİN YABA UÇAR
33	20150800071	HÜMEYRA	ÇOLAK	DOÇ. DR. SONER DOĞAN
34	20150800109	BAŞAK YAĞMUR	ÇUBUKÇU	YRD. DOÇ. DR. ALEV CUMBUL
35	20150800046	ATIL	DALGIÇOĞLU	DOÇ. DR. SONER DOĞAN
36	20140800080	BERFİN	DEMİREL	DOÇ. DR. SONER DOĞAN
37	20140800052	SERTAÇ	DOĞAN	DOÇ. DR. SONER DOĞAN
38	20150800082	MERT	DOLAŞTIR	PROF. DR. ECE GENÇ
39	20150800099	DIAB	DIALA	PROF. DR. ECE GENÇ
40	20150800059	SEVDE	EGE	YRD. DOÇ. DR. BİLGE GÜVENÇ TUNA
41	20140800057	ALEYNA	EKŞİ	YRD. DOÇ. DR. ÇİĞDEM ALTUNOK
42	20150800030	MERT	ENBİYAOĞLU	YRD. DOÇ. DR. DENİZ KIRAÇ
43	20150800058	İREMNUR	ERBAŞ	YRD. DOÇ. DR. DENİZ KIRAÇ
44	20150800038	RABİA	ERGÜN	YRD. DOÇ. DR. DENİZ KIRAÇ
45	20140800024	MERT	GAZİOĞLU	PROF. DR. EROL SEZER
46	20140800032	EYLÜL ECE	GÖĞEBAKAN	YRD. DOÇ. DR. HALE ARIK TAŞYIKAN
47	20140800065	BENGÜL	GÖLGE	YRD. DOÇ. DR. ÇİĞDEM ALTUNOK

48	20140800026	BATUHAN	GÜLER	YRD. DOÇ. DR. ÇİĞDEM ALTUNOK
49	20150800020	EDİS	HACILAR	YRD. DOÇ. DR. ÇİĞDEM ALTUNOK
50	20150800014	SENA ECE	ILGIN	YRD. DOÇ. DR. ÇİĞDEM ALTUNOK
51	20140800040	OĞUZ METE	İŞLEK	YRD. DOÇ. DR. ÇİĞDEM ALTUNOK
52	20150800048	SEREL	KABASAKAL	YRD. DOÇ. DR. ALEV CUMBUL
53	20140800029	ELİF EZEL	KADİROĞLU	YRD. DOÇ. DR. ALEV CUMBUL
54	20140800055	GÖKÇE ŞUBAT	KARAASLAN	YRD. DOÇ. DR. ALEV CUMBUL
55	20150800006	EMRE	KARAMAHMUTOĞLU	YRD. DOÇ. DR. ALEV CUMBUL
56	20140800066	BİRCAN	KASAP	YRD. DOÇ. DR. DENİZ KIRAÇ
57	20150800026	MURAT	KAMİLOĞLU	YRD. DOÇ. DR. DENİZ KIRAÇ
58	20130800054	BENGİSU	KESKİN	YRD. DOÇ. DR. HALE ARIK TAŞYIKAN
59	20140800011	EMİNE BÜŞRA	KITLIK	YRD. DOÇ. DR. DENİZ KIRAÇ
60	20150800092	TUBA	KOCA	DOÇ. DR. GÜLDAL İZBIRAK
61	20150800011	AYŞE GİZEM	KOÇ	YRD. DOÇ. DR. AYŞEGÜL KUŞKUCU
62	20150800041	KORHAN	KÖKÇE	YRD. DOÇ. DR. AYŞEGÜL KUŞKUCU
63	20150800043	EYLÜL	KÜÇÜK	DOÇ. DR. ÖZLEM TANRIÖVER
64	20140800047	CEMİLE	MİÇOOĞULLARI	DOÇ. DR. ÖZLEM TANRIÖVER
65	20150800094	ISRAA	MOHAMMED OMER MUSA	PROF. DR. İNCİ ÖZDEN
66	20150800073	MUSTAFA OĞULCAN	NADAR	PROF. DR. ECE GENÇ
67	20140800003	BERFİN	NARİN	DOÇ. DR. ÖZLEM TANRIÖVER
68	20150800086	RAHİM	RAHİMLİ	PROF. DR. EROL SEZER
69	20150800031	ÖZDEN	TÖMEK	PROF. DR. EROL SEZER
70	20150800003	ONUR	TUNCER	PROF. DR. EROL SEZER
71	20140800005	IRMAK SEDA	ORUÇ	PROF. DR. EROL SEZER
72	20150800066	MEMDUH	ÖZKAYA	DOÇ. DR. GÜLDEREN YANIKKAYA DEMİREL
73	20130800047	ÖZKAN	ÖZTÜRK	YRD. DOÇ. DR. SERDAR ÖZDEMİR
74	20150800088	ABDULA	SALAR	DOÇ. DR. GÜLDEREN YANIKKAYA DEMİREL
75	20160800103	MELİS	SALMAN	YRD. DOÇ. DR. ALEV CUMBUL
76	20150800047	CEVDET	SAN	DOÇ. DR. GÜLDEREN YANIKKAYA DEMİREL
77	20150800018	İLAYDA	SANCAR	DOÇ. DR. ÇAĞATAY ACUNER
78	20150800087	İSMET TAHSİN	SATIRLI	PROF. DR. İNCİ ÖZDEN
79	20140800010	BERK	SERBEST	DOÇ. DR. ÇAĞATAY ACUNER
80	20120800035	MUHAMMET SAİT	SEVİNDİK	YRD. DOÇ. DR. AYŞEGÜL KUŞKUCU
81	20140800037	CEMRE	ŞAHİN	DOÇ. DR. ÇAĞATAY ACUNER
82	20150800022	DOĞANCAN	ÜRETÜRK	DOÇ. DR. GÜLDEREN YANIKKAYA DEMİREL
83	20150800102	EZGİ	ÜŞÜMÜŞ	YRD. DOÇ. DR. SERDAR ÖZDEMİR
84	20150800070	SU	ÜNSAL	YRD. DOÇ. DR. SERDAR ÖZDEMİR
85	20140800028	YASMİNE	TEMUÇİN	YRD. DOÇ. DR. ARZU AKALIN
86	20150800080	REYDA	TIRPAN	YRD. DOÇ. DR. ARZU AKALIN
87	20150800033	YUSUF ÇAĞIN	TUNÇDEMİR	YRD. DOÇ. DR. ARZU AKALIN
88	20150800079	ALP	YAKUT	DOÇ. DR. MEHTAP KAÇAR
89	20140800051	NEZİHE	YANMAZ	DOÇ. DR. MEHTAP KAÇAR
90	20140800042	AYBERK	YENİKALE	DOÇ. DR. MEHTAP KAÇAR
91	20150800083	DİLARA	YETİŞ	PROF. DR. JALE ÇOBAN
92	20140800060	BUSE	YILDIRIM	PROF. DR. JALE ÇOBAN
93	20150800027	RONA	YILDIRIM	PROF. DR. JALE ÇOBAN
94	20130800055	GÖKBERK	YILDIZ	YRD. DOÇ. DR. BİLGE GÜVENÇ TUNA
95	20140800061	GİZEM AYNUR	YILMAZ	YRD. DOÇ. DR. BİLGE GÜVENÇ TUNA
96	20150800025	GÖKSU	YILMAZ	DOÇ. DR. SONER DOĞAN
97	20150800055	ŞERİF BURAK	YILMAZ	YRD. DOÇ. DR. BİLGE GÜVENÇ TUNA

CONTACT

Faculty Secretary :
Tel: +90 216 578 00 00 (3005)

Dean Secretary:
Tel: +90 216 578 05 05 – 06
Fax: +90 216 578 05 75

Student Affairs :
Tel: +90 216 578 06 86

Documents Affairs:
Tel: +90 216 578 05 93

Phase 3 Coordinator/ Co-coordinators:

Bayram Yılmaz, PhD, Prof. (Coordinator), 0216 578 00 (1675) / byilmaz@yeditepe.edu.tr

Hasan Aydın, MD, Assoc. Prof. (Co-coordinator), 0216 578 00 00 (4095) / haydin@yeditepe.edu.tr

Ayşegül Ç. Kuşkucu, MD, Asst. Prof. (Co-coordinator), 0216 578 00 00 (5777) / aysegul.kuskucu@yeditepe.edu.tr

Hale Arık Taşyıkan, MD, Asst. Prof. (Co-coordinator), 0216 578 00 00 (6300) / hale.arik@yeditepe.edu.tr

Serdar Özdemir, MD, Asst. Prof (Co-coordinator), 0216 578 00 00 (3066) / serdar.ozdemir@yeditepe.edu.tr

Barış Ata Borsa, Asst. Prof (Co-coordinator), 0216 578 00 / baris.borsa@yeditepe.edu.tr

Özlem Tanrıöver, MD, Assoc. Prof. (ICP Coordinator), 216 578 00 00 (3742) / otanriover@yeditepe.edu.tr

A. Arzu Akalın, MD, Asst. Prof. (ICP Co-coordinator), 216 578 00 00 (1525) /arzu.akalin@yeditepe.edu.tr

Address:

Yeditepe University Faculty of Medicine
İnönü Mah. Kayışdağı Caddesi,
26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul

Web : www.yeditepe.edu.tr
http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi
e-mail: tipfakdek@yeditepe.edu.tr

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE

İnönü Mah. Kayışdağı Caddesi,
26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul

+ 90 216 578 00 00

www.yeditepe.edu.tr
http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi
tipfakdek@yeditepe.edu.tr